Check for updates

OPEN ACCESS

EDITED BY Riccardo Inchingolo, Ospedale Generale Regionale F. Miulli, Italy

REVIEWED BY Maria Conticchio, Ospedale Generale Regionale Francesco Miulli, Italy Vincenzo Neri, University of Foggia, Italy

*CORRESPONDENCE Hongsheng Wu Itio crazywu2007@126.com Keqiang Ma Itio mkq9928@hotmail.com

RECEIVED 13 March 2023 ACCEPTED 13 November 2023 PUBLISHED 11 December 2023

CITATION

Wu H, Liao B, Cao T, Ji T, Huang J, Luo Y and Ma K (2023) Comparison of the safety profile, conversion rate and hospitalization duration between early and delayed laparoscopic cholecystectomy for acute cholecystitis: a systematic review and meta-analysis. *Front. Med.* 10:1185482. doi: 10.3389/fmed.2023.1185482

COPYRIGHT

© 2023 Wu, Liao, Cao, Ji, Huang, Luo and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Comparison of the safety profile, conversion rate and hospitalization duration between early and delayed laparoscopic cholecystectomy for acute cholecystitis: a systematic review and meta-analysis

Hongsheng Wu*, Biling Liao, Tiansheng Cao, Tengfei Ji, Jianbin Huang, Yumei Luo and Keqiang Ma*

Department of Hepatobiliary Pancreatic Surgery, Affiliated Huadu Hospital, Southern Medical University, Guangzhou, China

Background: Although the past decade has witnessed unprecedented medical progress, no consensus has been reached on the optimal approach for patients with acute cholecystitis. Herein, we conducted a systematic review and metaanalysis to assess the differences in patient outcomes between Early Laparoscopic Cholecystectomy (ELC) and Delayed Laparoscopic Cholecystectomy (DLC) in the treatment of acute cholecystitis. Our protocol was registered in the PROSPERO database (registration number: CRD42023389238).

Objectives: We sought to investigate the differences in efficacy, safety, and potential benefits between ELC and DLC in acute cholecystitis patients by conducting a systematic review and meta-analysis.

Methods: The online databases PubMed, Springer, and the Cochrane Library were searched for randomized controlled trials (RCTs) and retrospective studies published between Jan 1, 1999 and Jan 1, 2022.

Results: 21 RCTs and 13 retrospective studies with a total of 7,601 cases were included in this research. After a fixed-effects model was applied, the pooled analysis showed that DLC was associated with a significantly high conversion rate (OR: 0.6247; 95%CI: 0.5115–0.7630; z = -4.61, p < 0.0001) and incidence of postoperative complications (OR: 0.7548; 95%CI: 0.6197–0.9192; z = -2.80, p = 0.0051). However, after applying a random-effects model, ELC was associated with significantly shorter total hospitalization duration than DLC (MD: -4.0657; 95%CI: -5.0747 to -3.0566; z = -7.90, p < 0.0001).

Conclusion: ELC represents a safe and feasible approach for acute cholecystitis patients since it shortens hospitalization duration and decreases the incidence of postoperative complications of laparoscopic cholecystectomy.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=389238, identifier (CRD42023389238).

KEYWORDS

ELC, DLC, acute cholecystitis, review, meta-analysis

1 Introduction

Laparoscopic Cholecystectomy (LC) represents the standard of care treatment for patients requiring a cholecystectomy (1, 2). Acute cholecystitis has long been considered unsuitable for immediate surgical treatment. However, with the significant progress achieved in minimally invasive technology, the number of patients undergoing early laparoscopic surgery has significantly escalated (3, 4). Nevertheless, no consensus has been reached on the optimal timing for surgery. It has long been thought that the risk of intraoperative conversion to laparotomy and intraoperative or postoperative complications was increased with early laparoscopic cholecystectomy (ELC) due to gallbladder congestion and edema, severe peripheral inflammatory reaction, and undefined anatomy of the Calot triangle (5-8). However, in recent years, with an improved knowledge of the etiology of the abovementioned complications and surgical method improvements, the incidence of intraoperative and postoperative complications has markedly decreased (9, 10). Compared to delayed laparoscopic cholecystectomy (DLC), ELC for acute cholecystitis reportedly decreases the operative complications and conversion rate and shortens the hospitalization duration (11-13). Nonetheless, the optimal timing for surgery remains subject to debate, emphasizing the need for further research.

Even though the superiority of ELC over DLC has been increasingly documented in the literature, most studies were based on relatively small populations (14–17). Accordingly, we comprehensively studied the current literature to determine the efficiency, safety profile, and potential benefits of ELC in contrast to DLC.

2 Methods

2.1 Data extraction

Literature was included in strict compliance with the PICOS principle. The target population consisted of "patients with acute cholecystitis," the intervention was "LC," the comparison was conducted between "ELC" and "DLC," the outcomes consisted of "primary (conversion rate, intraoperative and postoperative complications) and secondary outcomes (Operation time, postoperative hospitalization duration and total hospitalization duration)" and the study design included "RCTs and retrospective studies." The reporting principle of this meta-analysis complied with the Preferred Reporting Items for Systematic Review and meta-analysis (PRISMA) 2020 protocol and Meta-analysis of Observational Studies in Epidemiology (MOOSE) declaration (18, 19).

2.2 Method of literature-search

Our literature search was carried out in July of 2022 with no restriction to countries, type of publication or language utilized in the following electronic databases: PubMed and the Cochrane Library. The following MeSH terms and combinations were utilized to search the title, abstract and keyword sections: *Early Laparoscopic Cholecystectomy OR Delay Laparoscopic Cholecystectomy AND acute cholecystitis AND complication AND timing*.

2.3 Inclusion and exclusion criteria

All reports included in our study were randomized controlled trials (RCTs) or retrospective comparative studies (cohort or casecontrol studies) contrasted ELC to DLC irrespective of age, and analyzed at least one of our primary outcomes. During literature screening, the following were excluded: Animal experimental studies, case reports, letters to the editor and review articles.

2.4 Data extraction and outcomes of interest

The primary outcomes included intraoperative complication rate, postoperative complication rate and conversion rate. Intraoperative complications were common complications encountered during surgery, such as intraoperative bleeding, bile duct injury, and gallbladder perforation. In contrast, postoperative complications were defined as bleeding, wound infection, bile leakage, and so on (20, 21). Conversion was defined as open cholecystectomy performed when the anatomical structure around the gallbladder was unclear, pericholecystic inflammation was severe or intraoperative bleeding could not be controlled. The secondary outcomes were operative time (min), postoperative hospitalization duration (d) and total hospitalization duration (d). Comparative indicators included at least one primary outcome and one secondary outcome.

2.5 Quality assessment and statistical methods

The Cochrane Collaboration's tool was used for assessing the risk of bias of RCTs graded as "low," "unclear" or "high risk" (22). The Newcastle-Ottawa Scale (NOS) was employed for the quality assessment of retrospective research based on criteria categorized into three dimensions: selection, comparability, and outcomes. A total score > 5 was associated with a low risk of bias (23).

R software Version 4.1.3 was used to perform the meta-analysis of included studies. For continuous data, "metacont" from "meta" package was used to pool the data, and "metabin" was used for binary data. The pooled results of continuous and binary data were compared using weighted mean difference (WMD) and Odds Ratio (OR), respectively. When $I^2 < 50\%$, we used a fixed-effects model for pooling WMD or OR and its 95% confidence interval. Otherwise, a random-effects model was selected. Heterogeneity among the studies was explored by using subgroup analysis and meta-regression. To assess the pooled results' stability, the "metainf" function was utilized for sensitivity analysis. Finally, Egger's test and funnel plots were used to indicate the publication bias. When Egger's *value of p*<0.05, the trim-and-fill approach was used for funnel plot asymmetry adjustment.

3 Results

3.1 Literature selection

861 studies were retrieved for a preliminary search in online databases PubMed, Springer, and Cochrane Library, according to the

PRISMA2020 statement. After 827 non-eligible studies were excluded, ultimately, 34 studies were analyzed in this meta-analysis. The literature screening process is shown in Figure 1.

3.2 Quality assessment of the included studies

The risk of bias in the included retrospective studies was evaluated using the Newcastle-Ottawa Scale based on the following domains subject selection, comparability and outcomes. The total scoring of each retrospective study was more than 5 points (Table 1). The Cochrane bias risk assessment system was employed to assess the included RCTs (Figure 2). Overall, the literature quality assessment found a low risk of bias for all included studies.

3.3 Characteristics of included studies

After literature screening and quality assessment, 34 studies were included in this meta-analysis, including RCTs (n = 21) (12, 14, 34–52) and retrospective studies (n = 13) (4, 13, 15, 24–33). The definition of ELC and DLC in the included studies was different. For ELC cases, laparoscopic cholecystectomy timing after acute cholecystitis onset was less than 24h (n=6) (12, 25, 35, 40, 46, 48), 48h (n=3) (24, 29, 51), 72h (n=15) (15, 26, 30–33, 36, 39, 42, 43, 45, 47, 49, 50, 52), 4 days (n=3) (4, 37, 41), 5 days (n=1) (34), and 7 days (n=3) (13, 28, 38). For the 3 remaining studies (14, 27, 44), the specific timing for ELC was not mentioned, and the authors just proposed performing laparoscopic cholecystectomy as early as possible. Regarding the definition of DLC, laparoscopic cholecystectomy timing after acute cholecystitis onset was set to more than 24h (n=1) (25), 48h (n=2)





TABLE 1 Quality assessment of retrospective research base on Newcastle-Ottawa Scale.

| Author(Year) | : | Selection of st | udy population | | Comparability | | Outcome | | Total Scoring |
|---|---|---|---|--|---------------|--------------------------|---|---|------------------|
| | Representativeness of the exposure cohort | Selection of non- exposed cohort | Ascertainment of exposure to implants | Demonstration that outcome of interest was not present at the start of study | | Assessment of outcome | Was follow up long enough for outcomes to occur | Adequacy of follow up of cohorts | |
| Garber, SM 1997 (4) | * | * | * | * | * | * | * | | 7 |
| Madan,AK 2002 (24) | * | * | | * | | * | * | * | 6 |
| Stevens, KA 2006 (25) | * | | * | * | * | * | | * | 6 |
| González- Rodríguez,F.J 2009 (26) | * | * | | * | * | * | * | * | 7 |
| Chang, TC 2009 (27) | * | * | * | | * | | * | * | 6 |
| Choi, SB 2011 (28) | * | * | * | * | * | * | * | * | 8 |
| Falor, AE 2012 (29) | * | * | * | * | * | * | * | | 7 |
| Zhu, Bin 2012 (30) | * | * | * | * | * | | * | * | 7 |
| Panagiotopoulou 2012 (13) | | * | | * | * | * | | * | 5 |
| Han, IW 2012 (15) | * | | * | * | * | | * | | 5 |
| Kwon, YJ 2013 (31) | * | * | | * | * | | * | * | 6 |
| Gomes,RM 2013 (32) | * | * | * | * | * | | * | * | 7 |
| Wu Hongsheng 2021 (33) | * | * | | * | * | * | | * | 6 |



(24, 29), 72 h (n=7) (15, 26, 30–32, 39, 42), 6 weeks (*n*=14) (12, 27, 35, 36, 38, 40, 41, 44, 45, 47–50, 52), 12 weeks (*n*=1) (43) and 15 weeks (n=1) (34). In 7 studies (4, 13, 14, 28, 33, 46, 51), the timing ranged from 72 h to 6 weeks, while no mention of the specific timing for DLC was found in 1 study (37). The details of the studies included in our report are shown in Table 2.

3.4 Primary outcomes synthesis

I² values less than 50% were obtained for the pooling conversion rate (I² = 43%, τ 2=0.2548, *p*=0.01), intraoperative complications (*I*² = 18.0%, τ 2=0.2977, *p*=0.28) and postoperative complications (*I*² = 19.0%, τ 2<0.0001, *p*=0.17). Accordingly, we utilized a fixed-effects model to conduct the meta-analysis of primary outcomes. No significant differences in intraoperative complications were found between ELC and DLC (OR: 1.2616; 95%CI: 0.8998–1.7689; z=1.35, *p*=0.1778) (Figure 3B). However, compared with ELC, DLC associated with a high conversion rate (OR: 0.6247; 95%CI: 0.5115–0.7630; z=-4.61, *p*<0.0001) (Figure 3A) and postoperative complication incidence (OR: 0.7548; 95%CI: 0.6197–0.9192; z=-2.80, *p*=0.0051) (Figure 3C).

3.5 Secondary outcomes synthesis

Significant heterogeneity was found among studies that assessed the secondary outcomes with I² values above 50% obtained for the operation time (I² =96%, τ 2=202.6737, p<0.01), postoperative hospitalization duration (I² =98%, τ 2=2.4357, p<0.01) and total hospitalization duration (I² =98%, τ 2=7.6196, p<0.01). Accordingly, a random-effects model was applied for data synthesis. The pooled estimates revealed no marked differences in operation time (MD: 0.4594; 95%CI: -5.3527 to 6.2716; z=0.16, p=0.8769) (Figure 4A) and postoperative hospitalization duration (MD: -0.1088; 95%CI: -8.332 to 0.6157; z=-0.29, p=0.7685) (Figure 4B) between ELC and DLC. In contrast, ELC was associated with significantly shorter total hospitalization duration than with DLC (MD: -4.0657; 95%CI:-5.0747 to -3.0566; z = -7.90, p < 0.0001) (Figure 4C).

3.6 Subgroup analysis for exploration of sources of heterogeneity

Given that significant heterogeneity was found in operation time, postoperative hospitalization duration and total hospitalization duration, subgroup analysis was conducted according to the study design (e.g., RCT or Retrospective research), location (e.g., Asia, America or Europe), ELC definition (e.g., Timing of laparoscopic cholecystectomy after the onset of acute cholecystitis less than 72 h or other definitions) and year of study (e.g., Studies before 2013 or since and after 2013). Subgroup analysis according to operation time indicated no significant significance between the subgroups in the study design (heterogeneity test: $I^2 = 96\%, \tau^2 = 202.674, p < 0.01,$ random effect model: $\chi^2 = 0.97$, df = 1, p = 0.33) (Appendix 1), ELC definition (heterogeneity test: $I^2 = 96\%$, $\tau^2 = 202.674$, p < 0.01, random effect model: $\chi^2 = 0.01$, df = 1, p = 0.92) (Appendix 2) and year of study (heterogeneity test: $I^2 = 96\%, \tau^2 = 202.674, p < 0.01$, random effect model: $\chi^2 = 0.80$, df = 1, p = 0.37) (Appendix 3). However, after subgroup analysis according to location, compared with America and Europe, ELC was associated with longer operation time than DLC in Asia (heterogeneity test: $I^2 = 96\%$, $\tau^2 = 202.674$, p < 0.01, random effect model: $\chi^2 = 18.65$, df = 2, p < 0.01) (Figure 5). Subgroup analysis according to the total hospitalization duration revealed no significant differences between subgroups for the study design (heterogeneity test: $I^2 = 98\%, \tau^2 = 7.6196, p < 0.01,$ random effect model: $\chi^2 = 0.38$, df=1, p=0.54) (Appendix 4), ELC definition (heterogeneity test: $I^2 = 98\%, \tau^2 = 7.6196, p < 0.01, random effect model: \chi^2 = 0.96, df = 1,$ p=0.33) (Appendix 5) and year of study (heterogeneity test: $I^2 = 98\%, \tau^2 = 7.6196, p < 0.01, random effect model: \gamma^2 = 0.07, df = 1,$ p = 0.79) (Appendix 6). However, ELC was associated with longer total hospitalization duration than DLC in Asia compared with America and Europe (heterogeneity test: $I^2 = 98\%$, $\tau^2 = 7.6196$, p < 0.01, random effect model: $\chi^2 = 16.60$, df = 2, p < 0.01) (Figure 6).

TABLE 2 The characteristics of including studies.

| Author | Year | Country | Study design | Patier ELC | nts'NO. DLC | Pathological characteristics | Definition of ELC | Definition of DLC | Observed outcomes |
|--------------------------------|------|--------------|-----------------|---------------|-----------------------|----------------------------------|----------------------|----------------------|-----------------------|
| Lo, CM (34) | 1996 | China | RCT | 27 | 25 | NA | <5 days | >15 weeks | iii, v, vi |
| Garber, SM (4) | 1997 | USA | Retrospective | 109 | 85 | suppurative gangrenous | <4 days | >4 days | i, iii, iv, vi |
| Lai, PB (35) | 1998 | China | RCT | 53 | 52 | gangrenous | <24 h | 6–8 weeks | i, iii, iv, v, vi |
| Lo, CM (36) | 1998 | China | RCT | 45 | 41 | NA | <72 h | 8–12 weeks | i, iii, iv, v, vi |
| Chandler,CF (14) | 2000 | USA | RCT | 21 | 22 | suppurative | No mention | >5 days | i, ii, iii, iv, vi |
| Bhattacharya (37) | 2002 | UK | RCT | 33 | 17 | NA | <4 days | No mention | iii, iv, v, vi |
| Madan, AK (24) | 2002 | USA | Retrospective | 14 | 31 | NA | <48 h | >48 h | i, iii, iv, v, vi |
| Johansson,M (38) | 2003 | Sweden | RCT | 74 | 69 | NA | <7 days | 6–8 weeks | i, iii, iv, vi |
| Serralta, AS (39) | 2003 | Spain | RCT | 82 | 87 | phlegmonous gangrenous | <72 h | >72 h | i, iii, iv, v, vi |
| Kolla, SB (40) | 2004 | India | RCT | 20 | 20 | NA | <24 h | 6–12 weeks | i, ii, iii, iv, v, vi |
| Akyürek N (41) | 2005 | Turkey | RCT | 31 | 30 | NA | <4 days | 8 weeks | i, v, vi |
| Stevens, KA (25) | 2006 | USA | Retrospective | 132 | 121 | suppurative | <24 h | >24 h | i, iii, iv, vi |
| Al-Mulhim (42) | 2008 | Saudi Arabia | RCT | 82 | 114 | NA | <72 h | >72 h | i, iii, iv, v, vi |
| González- Rodríguez,FJ (26) | 2009 | Spain | Retrospective | 102 | 434 | empyema suppurative | <72 h | >72 h | i, iii, iv, v, vi |
| Macafee,DA (43) | 2009 | UK | RCT | 36 | 36 | NA | <72 h | >12 weeks | i, ii, iii, v, vi |
| Yadav, RP (44) | 2009 | Nepal | RCT | 21 | 22 | NA | No mention | 6–8 weeks | i, ii, iii, iv, vi |
| Chang, TC (27) | 2009 | China | Retrospective | 56 | 33 | suppurative | No mention | >6 weeks | iii, iv, v, vi |
| Choi, SB (28) | 2011 | Korea | Retrospective | 57 | 59 | NA | < 7 days | >7 days | iii, iv, v, vi |
| Falor, AE (29) | 2012 | USA | Retrospective | 117 | 186 | NA | <48 h | >48 h | i, iii, vi |
| Zhu, Bin (30) | 2012 | China | Retrospective | 34 | 99 | simple phlegmonous gangrenous | <72 h | >72 h | iii, iv, v, vi |
| Panagiotopoulou (13) | 2012 | UK | Retrospective | 21 | 15 | NA | < 7 days | >7 days | iii, vi |
| Han, IW (15) | 2012 | Korea | Retrospective | 21 | 46 | simple suppurative | <72 h | >72 h | 1, ii, iii, iv, v, v |
| Gul, R (45) | 2013 | India | RCT | 30 | 30 | NA | <72 h | 6–8 weeks | i, iii, iv, vi |
| Gutt, CN (46) | 2013 | Germany | RCT | 304 | 314 | NA | <24 h | >7 days | i, ii, iii, vi |
| Kwon, YJ (31) | 2013 | Korea | Retrospective | 33 | 28 | empyema | <72 h | >72 h | i, iii, iv, v, vi |
| Gomes, RM (32) | 2013 | India | Retrospective | 21 | 40 | simple phlegmonous gangrenous | <72 h | >72h | iv, vi |
| Ozkardeş,AB (47) | 2014 | Turkey | RCT | 30 | 30 | NA | <72 h | 6–8 weeks | 1, ii, iii, iv, vi |
| Agrawal, R (48) | 2015 | India | RCT | 25 | 25 | suppurative | <24 h | 6–8 weeks | i, ii, iii, iv, v, vi |
| Rajcok, M (49) | 2016 | Slovakia | RCT | 31 | 31 | NA | <72 h | 6–8 weeks | i, iii, iv, vi |
| Roulin, D (50) | 2016 | Switzerland | RCT | 42 | 44 | NA | <72 h | >6 weeks | i, ii, iii, iv, vi |
| Khalid (12) | 2017 | Pakistan | RCT | 90 | 90 | phlegmonous gangrenous | <24 h | 6-12 weeks | i, ii, iii, iv, v |
| Davoodabadi (51) | 2020 | Iran | RCT | 104 | 104 | NA | <48 h | >7 days | i, iii, iv, vi |
| Isil, RG (52) | 2021 | Turkey | RCT | 88 | 88 | NA | <72 h | 4–8 weeks | i, iii, iv, vi |
| Wu,Hongsheng (33) | 2021 | China | Retrospective | 3,085 | 62 | NA | <72 h | >7 days | i, iii, iv, v |

ELC, Early Laparoscopic Cholecystectomy; DLC, Delay Laparoscopic Cholecystectomy; RCT, Randomized Controlled Trial; i, Conversion Rate; ii, Intraoperative Complications; iii, Postoperative Complications; iv, Operation Time; v, Postoperative Hospital Stay Time; vi, Total Hospital Stay Time.

| 1 | Study | Event | s | ELC Total | Events | DLC Total | Weight | Odds Ratio MH, Fixed, 95% | 6 CI | Odds Ra MH, Fixed, 9 | | |
|-----|---|---|--|---|--|--|--|---|--|-------------------------|--------------|---------|
| 1 | Garber, S.M1997 | | 2 | 109 | 27 | 05 | 11.9% | 0.04 [0.01; 0.17 | 71 | | | |
| | Lai, P.B1998 | 1 | 1 | 53 | 27 9 | 85 37 | 3.4% | 0.81 [0.30; 2.22 | | | - | |
| | Lo, C.M1998 | | 5 | 45 | 9 | | 3.3% | 0.44 [0.14; 1.46 | 6] | | | |
| | Chandler CF2000 | | 5 | 21 | 8 | | 2.4% | 0.55 [0.14; 2.06 | | | | |
| | Madan,AK2002 | | 0 | 14 | 9 | | 2.3% | 0.08 [0.00; 1.5] | | | | |
| | Johansson, M2003 | 2 | 23 2 | 74 82 | 20 15 | 69 87 | 5.7% 5.7% | 1.10 [0.54; 2.26 0.12 [0.03; 0.54 | | | - | |
| | Serralta, A.S2003 Kolla SB2004 | | 5 | 20 | 5 | | 1.5% | 1.00 [0.24; 4.18 | | | | |
| | Akyürek, N2005 | | 2 | 31 | 4 | | 1.5% | 0.45 [0.08; 2.65 | | | _ | |
| | Stevens, K.A2006 | 1 | 12 | 132 | 7 | | 2.7% | 1.63 [0.62; 4.28 | | | _ | |
| | Al-Mulhim2008 | | 2 | 82 | 8 | | 2.6% | 0.33 [0.07; 1.60 | 0] | | | |
| | Macafee DA2009 | | 1 | 36 | 1 | 36 | 0.4% | 1.00 [0.06; 16.6. | | | | |
| | Yadav RP2009 González–Rodríguez, F.J200 | 0 | 4 8 | 21 102 | 3 80 | | 0.9% 11.2% | 1.49 [0.29; 7.63 0.38 [0.18; 0.81 | | | | |
| | Falor, A.E2012 | 9 | 3 | 117 | 14 | 186 | 4.2% | 0.32 [0.09; 1.15 | | | | |
| | Han, I.W2012 | | 0 | 21 | 3 | | 0.9% | 0.29 [0.01; 5.85 | | • | | |
| | Gul R2013 | | 3 | 30 | 4 | 30 | 1.4% | 0.72 [0.15; 3.54 | | | _ | |
| | Gutt2013 | 1 | 14 | 304 | 20 | | 7.5% | 0.71 [0.35; 1.43 | | | | |
| | Kwon, Y.J2013 | | 4 4 | 33 30 | 0 | | 0.2% | 8.69 [0.45; 168.9 | | | • | |
| | Ozkardes AB2014 Agrawal R2015 | | 4 | 25 | 2 | | 0.2% 0.7% | 10.36 [0.53; 201.4 2.19 [0.36; 13.22 | | | · · · | |
| | Roulin D2016 | | 1 | 42 | 0 | | 0.2% | 3.22 [0.13; 81.19 | | | | |
| J | Rajcok, M2016 | | 1 | 31 | 5 | 31 | 1.9% | 0.17 [0.02; 1.58 | 8] | | | |
| | Khalid2017 | 1 | 14 | 90 | 13 | 90 | 4.4% | 1.09 [0.48; 2.47 | | | - | |
| | Davoodabadi2020 | | 6 | 104 | 7 | | 2.6% | 0.85 [0.28; 2.62 | | | - | |
| | Wu,Hongsheng2021 Isil, R.G2021 | 3 | 37 0 | 1503 88 | 52 2 | | 19.3% 1.0% | 0.77 [0.50; 1.18 0.20 [0.01; 4.13 | | | | |
| | isii, R.02021 | | U | 00 | 2 | 00 | 1.070 | 5.20 [0.01; 4.13 | -1 - | | | |
| , | Total (95% CI) | | | 3240 | | 3809 | 100.0% | 0.62 [0.51; 0.76 | 6] | • | | |
| J | Heterogeneity: $Tau^2 = 0.2548$ | ; Chi ² = | 45.5 | 59, $df = 2$ | (P = 0. | 01); I ² = | 43% | | · _ | 1 1 | 1 | |
| | | | | | | | | | 0.01 | 0.1 1 | 10 | 100 |
| 3 | | ELC | | | DLC | | | dds Ratio | | Odds Ratio | | |
| - | Study Events | Total | | Events | Total | Weigh | t MH, | Fixed, 95% CI | N | 4H, Fixed, 95% | % CI | |
| | Chandler CF2000 | 21 | | | 2 22 | 3.9% | 6 1.05 | [0.13; 8.24] | | | | |
| | Kolla SB2004 | | | | 0 20 | 1.0% | | [0.25; 123.08] | | | • | |
| | Macafee DA2009 | 36 | | | 1 36 | 2.1% | | [0.06; 16.63] | | t: | | |
| | Yadav RP2009 10 | | | | 5 22 | 5.6% | | [0.83; 11.51] | | | | |
| - 1 | Han, I.W2012 4 | | | | 2 46 | 2.2% | | [0.87; 30.92] | | t: | • | |
| | | | | | | | | | | | | |
| | Gutt2013 30 | | | 3 | | 63.9% | | [0.55; 1.57] | | | | |
| 1 | Ozkardes AB2014 4 | 30 | | | 0 30 | 0.9% | 6 10.36 | [0.53; 201.45] | | _ | | |
| 1 | Ozkardes AB2014 Agrawal R2015 2 | 30 25 | | | 0 30 0 25 | 0.9% 1.0% | 6 10.36 6 5.43 | [0.53; 201.45] [0.25; 118.96] | | | • | |
| • | Ozkardes AB2014 4 | 30 25 42 | | | 0 30 | 0.9% | 5.43 5.22 | [0.53; 201.45] | | | • | |
| • | Ozkardes AB2014 Agrawal R2015 2 Roulin D2016 Khalid2017 6 | 30 25 42 90 | | | 0 30 0 25 0 44 9 90 | 0.9% 1.0% 1.0% 18.4% | 10.36 5.43 3.22 0.64 | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] | | | • | |
| | Ozkardes AB2014 4 Agrawal R2015 2 Roulin D2016 1 Khalid2017 6 Total (95% CI) | 30 25 42 90 610 | i ² = | | 0 30 0 25 0 44 9 90 649 | 0.9% 1.0% 1.0% 18.4% 100.0% | 10.36 5.43 3.22 0.64 1.30 | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] | | | • | |
| | Ozkardes AB2014 Agrawal R2015 2 Roulin D2016 Khalid2017 6 | 30 25 42 90 610 | i ² = | | 0 30 0 25 0 44 9 90 649 | 0.9% 1.0% 1.0% 18.4% 100.0% | 10.36 5.43 3.22 0.64 1.30 | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] | 0.01 | 0.1 1 | + + 10 | 100 |
| | Ozkardes AB2014 4 Agrawal R2015 2 Roulin D2016 1 Khalid2017 C Total (95% CI) Heterogeneity: Tau ² = 0.2 | 30 25 42 90 610 977 ; Chi | | 11.01, | $\begin{array}{cccc} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ 649 \\ df = 9 (P \\ \end{array}$ | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 | 10.36 5.43 3.22 0.64 0.64 1.30 $1^2 = 18$ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio | | Odds Ra | atio | 100 |
| | Ozkardes AB2014 4 Agrawal R2015 2 Roulin D2016 1 Khalid2017 6 Total (95% CI) | 30 25 42 90 610 | | 11.01, | $\begin{array}{cccc} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ 649 \\ df = 9 (P \\ \end{array}$ | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 | 10.36 5.43 3.22 0.64 0.64 1.30 $1^2 = 18$ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % | | | atio | 100 |
| | Ozkardes AB2014 4 Agrawal R2015 2 Roulin D2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 | 30 25 42 90 610 977 ; Chi | ts 6 | ELC Total | $\begin{array}{cccc} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline 649 \\ df = 9 \ (P \\ \hline Events \\ 5 \\ \end{array}$ | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 25 | $\begin{array}{c} 10.36\\ 5 & 5.43\\ 6 & 3.22\\ 5 & 0.64\\ \end{array}$ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.34 | 6 CI | Odds Ra | atio | 100 |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin D2016 1 Khalid2017 6 Total (95% CI) 1 Heterogeneity: Tau ² = 0.2 2 Study 1 Lo, C.M1996 6 Garber, S.M1997 1 | 30 25 42 90 610 977 ; Chi | ts 6 3 | ELC Total 27 109 | $\begin{array}{r} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline 649 \\ df = 9 \ (P \\ \hline Events \\ \hline 5 \\ 11 \\ \end{array}$ | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 25 85 | $\frac{10.36}{5} = \frac{10.36}{5.43}$ $\frac{5}{5} = \frac{3.22}{0.64}$ $\frac{1.30}{5} = \frac{1.30}{12} = 18$ Weight $\frac{1.8\%}{5.2\%}$ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.34 0.19 [0.05; 0.7] | 6 CI | Odds Ra | atio | 100 |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 | 30 25 42 90 610 977 ; Chi | ts 6 3 5 | ELC Total 27 109 53 | 0 30 0 25 0 44 9 90 649 df = 9 (P Events | 0.9% 1.0% 1.0% 18.4% = 0.28 DLC Total 25 85 38 | $\frac{10.36}{5} = \frac{10.36}{5} = \frac{10.36}{5} = \frac{1.30}{5} = $ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4] | 6 CI (4] (1] (3] | Odds Ra | atio | 100 |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin D2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 | 30 25 42 90 610 977 ; Chi | 6 3 5 6 | ELC Total 27 109 53 45 | $\begin{array}{cccc} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ 649 \\ df = 9 \ (P \\ \hline \\ $ | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 25 85 38 41 | $\begin{array}{c} & 10.36 \\ 5 & 5.43 \\ 5 & 3.22 \\ 0 & 0.64 \\ \hline & 1.30 \\ 0 \\ 0 \\ 0 \\ 1.8\% \\ \hline & 1.4\% \\ 1.4\% \\ 4.7\% \end{array}$ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3- 0.19 [0.05; 0.7 1.22 [0.27; 5.4: 0.37 [0.12; 1.1] | 6 CI (4] (1] (3) (1] | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 | 30 25 42 90 610 977 ; Chi | ts 6 3 5 | ELC Total 27 109 53 | 0 30 0 25 0 44 9 90 649 df = 9 (P Events | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 25 85 38 41 22 | $\frac{10.36}{5} = \frac{10.36}{5} = \frac{10.36}{5} = \frac{1.30}{5} = $ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4 0.37 [0.12; 1.1] 1.05 [0.13; 8.2 ² | 6 CI (4] (1] (3] (1] (4] | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin D2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 | 30 25 42 90 610 9777 ; Chi | 6 3 5 6 2 2 0 | ELC Total 27 109 53 45 21 33 14 | $\begin{array}{cccc} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline & 649 \\ \hline & 640 \\ $ | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 25 85 38 41 22 17 31 | | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.03 [0.09; 12.2 0.28 [0.01; 5.8 | 6 CI (4] (1] (3] 1] (4] 27] (1] - | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 | 30 25 42 90 610 9777 ; Chi | ts 6 3 5 6 2 2 0 13 | ELC Total 27 109 53 45 21 33 14 74 | 0 30 0 25 0 44 9 90 649 df = 9 (P Events 5 11 13 3 12 2 1 1 3 7 | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 25 85 38 41 222 17 31 69 | | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1] 1.05 [0.13; 8.2- 1.05 [0.13; 8.2- 0.28 [0.01; 5.8 1.89 [0.71; 5.0] | 6 C1 (4] (1] (3] 1] (4] (4] (27) (31) (5) (5) | Odds Ra | atio | 100 |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2000 Serralta, A.S2003 | 30 25 42 90 610 9777 ; Chi | 6 3 5 6 2 2 0 13 10 | ELC Total 27 109 53 45 21 33 14 74 82 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ 649 \\ df = 9 \\ P \\ \hline \\ \hline$ | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 25 85 38 84 1 22 17 31 31 987 | $\begin{array}{c} \textbf{i} 10.36\\ \textbf{i} 5.43\\ \textbf{j} 3.22\\ \textbf{j} 0.64\\ \textbf{j} \textbf{j} \textbf{l} = 18\\ \textbf{Weight}\\ \hline 1.8\%\\ \textbf{5.2\%}\\ 1.4\%\\ 4.7\%\\ 0.8\%\\ 0.5\%\\ 0.9\%\\ 2.6\%\\ 4.8\%\\ \end{array}$ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.13; 82 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.89 [0.71; 5.0: 0.79 [0.33; 1.9] | 6 C1 (4] (1] (3] 1] (4] 27] (4] 27] (5] 22] | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin D2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 | 30 25 42 90 610 9777 ; Chi | ts 6 3 5 6 2 2 0 13 10 2 | ELC Total 27 109 53 45 21 33 14 74 82 20 | 0 30 0 25 0 44 9 90 649 df = 9 (P Events 111 3 12 2 1 3 3 3 3 | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 25 85 38 41 222 17 31 69 87 20 | $\begin{array}{c} & 10.36 \\ 5 & 5.43 \\ 5 & 3.22 \\ 0 & 0.64 \\ \end{array}$ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.13; 8.2 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.89 [0.71; 5.0 0.79 [0.33; 1.9] 0.63 [0.09; 4.2] | 4 CI 44] 13] 13] 14] 27] 44] 22] 22] 24] | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2000 Serralta, A.S2003 | 30 25 42 90 610 9777 ; Chi | 6 3 5 6 2 2 0 13 10 | ELC Total 27 109 53 45 21 33 14 74 82 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ 649 \\ df = 9 \\ P \\ \hline \\ \hline$ | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 255 38 41 225 38 41 227 31 69 87 20 121 | $\begin{array}{c} \textbf{i} 10.36\\ \textbf{i} 5.43\\ \textbf{j} 3.22\\ \textbf{j} 0.64\\ \textbf{j} \textbf{j} \textbf{l} = 18\\ \textbf{Weight}\\ \hline 1.8\%\\ \textbf{5.2\%}\\ 1.4\%\\ 4.7\%\\ 0.8\%\\ 0.5\%\\ 0.9\%\\ 2.6\%\\ 4.8\%\\ \end{array}$ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.13; 82 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.89 [0.71; 5.0: 0.79 [0.33; 1.9] | 6 Cl 14] 13] 13] 13] 13] 13] 13] 14] 14] 27] 13] 27] 22] 22] 24] 28] | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 | 30 25 42 90 610 9777 ; Chi | ts 6 3 5 6 2 2 0 13 10 2 5 | ELC Total 27 109 53 45 21 33 14 74 82 20 132 | 0 30 0 25 0 44 9 90 649 649 Events 11 3 12 2 2 1 3 3 7 13 3 7 7 | 0.9% 1.0% 1.0% 18.4% 100.0% = 0.28 DLC Total 25 85 38 41 22 17 31 69 87 20 121 114 | $\begin{array}{c} & 10.36\\ 5 & 5.43\\ 5 & 3.22\\ 0 & 0.64\\ \end{array}$ | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1] 1.05 [0.13; 8.2; 1.03 [0.09; 12.2 0.28 [0.01; 5.8; 0.79 [0.33; 1.9; 0.63 [0.09; 4.2; 0.64 [0.20; 2.0] | 6 CI 44] 13] 13] 14] 44] 47] 47] 44] 48] 44] | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB204 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 | 30 25 42 90 610 9777 ; Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 | ELC Total 27 109 53 45 21 33 45 21 33 45 21 33 45 21 20 132 82 60 36 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | 0.9% 1.0% | $\begin{array}{c} \textbf{i} 10.36\\ \textbf{i} 5.43\\ \textbf{j} 3.22\\ \textbf{i} 0.64\\ \textbf{i} 0.64\\ \textbf{i} \textbf{j}^2 = 18\\ \hline \\ \textbf{Weight} \\ \hline \\ \textbf{Weight} \\ \hline \\ \textbf{1.8\%} \\ \textbf{5.2\%} \\ \textbf{1.4\%} \\ \textbf{4.7\%} \\ \textbf{0.8\%} \\ \textbf{0.5\%} \\ \textbf{0.9\%} \\ \textbf{2.6\%} \\ \textbf{4.8\%} \\ \textbf{1.2\%} \\ \textbf{3.0\%} \\ \textbf{2.7\%} \\ \textbf{0.3\%} \end{array}$ | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.95% 1.14 [0.30; 4.95% 1.14 [0.30; 4.95% 1.14 [0.30; 4.07] 1.22 [0.27; 5.4; 0.37 [0.12; 1.1] 1.05 [0.13; 8.2; 1.03 [0.09; 1.2; 0.28 [0.01; 5.8] 8.89 [0.71; 5.0; 0.79 [0.33; 1.9; 0.63 [0.09; 4.2] 0.64 [0.20; 2.0] 0.64 [0.20; 2.0] 0.65 | 6 CI (4] (4] (3] (4] (4] (4] (5] (4] (4] (4] (4] (4] (4] (4] (4 | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agrawal R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang,T C2008 Macafee DA2009 Yadav RP2009 | 30 25 42 90 610 977 : Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 | ELC Total 27 109 53 45 21 33 14 82 20 20 132 82 56 36 21 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | $\begin{array}{c} 0.99\\ 1.09\\ 1.09\\ 1.09\\ 1.09\\ 10.09\\ \end{array}$ | $\begin{array}{c} \mathbf{i} 10.36\\ \mathbf{b} 5.43\\ \mathbf{b} 5.43\\ \mathbf{b} 5.43\\ \mathbf{b} 5.43\\ \mathbf{b} 5.43\\ \mathbf{b} 1.5\\ \mathbf{c} 3.22\\ \mathbf{b} 0.64\\ \mathbf{b} 1.30\\ \mathbf{c} 1.30\\ \mathbf{c} 1.30\\ \mathbf{c} 1.30\\ \mathbf{c} 1.30\\ \mathbf{c} 1.4\%\\ \mathbf{c} 5.2\%\\ \mathbf{c} 1.4\%\\ \mathbf{c} 5.2\%\\ \mathbf{c} 1.4\%\\ \mathbf{c} 5.2\%\\ \mathbf{c} 1.4\%\\ \mathbf{c} 0.5\%\\ \mathbf{c} 0.9\%\\ \mathbf{c} 6\%\\ \mathbf{c} 0.9\%\\ \mathbf{c} 3.0\%\\ \mathbf{c} 3.0\%\\ \mathbf{c} 3.0\%\\ \mathbf{c} 0.5\%\\ \mathbf{c} 0.5\%$ | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3, 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.09; 12.2 0.28 [0.01; 5.8 1.89 [0.71; 5.0; 0.79 [0.33; 1.9; 0.63 [0.09; 4.2; 0.64 [0.20; 2.00 0.09 [0.00; 1.5; 5.74 [0.30; 110.1 2.29 [0.62; 8.4] 0.48 [0.14; 1.77 | 6 Cl 44] 13] 13] 13] 14] 27] 15] 22] 24] 44] 43] 44] 13] 10] | Odds Ra | atio | 100 |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macae DA2009 Yadav RP2009 González-Rodríguez, FJ200 | 30 25 42 90 610 977 : Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 | ELC Total 27 109 53 45 21 14 74 82 20 132 20 132 20 132 20 132 20 132 20 132 20 132 20 132 20 132 20 132 20 132 20 133 20 14 20 14 20 20 14 20 20 20 20 20 20 20 20 20 20 20 20 20 | 0 30 0 25 0 44 9 90 649 649 649 111 3 12 2 1 1 3 7 7 0 0 4 4 10 77 7 | 0.99 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.02 | i 10.36 i 10.36 i 3.22 i 0.64 i 3.22 i 1.30 i 1.30 i 1.2 i 1 ² = 18 Weight 1.8% i 1, 1 ² = 18 0.8% 0.3% 0.8% 0.130 0.8% 0.8% 0.8% 0.8% 0.8% 0.3% 0.13% 0.8% 0.8% 0.13 | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4 0.37 [0.12; 1.1 1.05 [0.13; 8.2 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.89 [0.71; 5.0 0.79 [0.33; 1.9] 0.63 [0.09; 4.22 0.64 [0.20; 2.04 0.09 [0.00; 1.5.7 5.74 [0.30; 110.1 2.29 [0.62; 8.4 0.48 [0.14; 1.77 0.45 [0.22; 0.9] | 6 CI (4] (3] (3] (4] (4] (4] (5] (5] (2] (4] (8] (8] (8] (8] (13) (13) (13) (13) (13) (14) (15) (1 | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla B2004 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 Yadav RP2009 González-Rodríguez, F.J200 Choi,S B2011 | 30 25 42 90 610 977 : Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 | ELC Total 27 109 53 21 33 45 21 33 14 74 82 20 132 82 56 62 1 102 85 57 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | $\begin{array}{c} 0.99\\ 1.09\\ 1.09\\ 1.09\\ 1.09\\ 10.02\\ 10.02\\ 10.02\\ \hline \end{array}$ | $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.37 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.13; 8.2 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.9 [0.71; 5.0; 0.79 [0.33; 1.92; 0.64 [0.00; 1.5; 5.74 [0.30; 110] 2.29 [0.62; 8.4 0.48 [0.14; 1.77 0.45 [0.22; 0.92; 1.04 [0.25; 4.33] 1.04 [0.25; 4.33] | 6 CI (4] (3] (1] (4] (4] (4] (5] (5] (5] (4] (8] (8] (4] (8] (8] (4] (8] (9] (9] (9] (9] (9] (9] (9] (9 | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agrawal R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2000 Serralta, A.S2003 Serralta, A.S2003 Sorralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang,T C2008 Macafee DA2009 Yadav RP2009 González–Rodríguez, F.J200 Choi,S B2011 Falor, A.E2012 | 30 25 42 90 610 977 : Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 | ELC Total 27 109 53 45 21 33 45 21 33 14 74 82 20 132 82 56 6 36 21 102 57 7117 | 0 30 0 25 0 44 9 90 649 649 649 649 649 11 3 12 2 11 3 12 2 1 13 3 7 7 0 4 10 77 4 5 11 12 2 12 12 12 12 12 12 12 | 0.99 1.09 1.09 18.4% 100.0% EXAMPLA 100.0% DLC Total 25 85 85 85 85 85 85 84 11 22 17 31 69 7 20 121 114 433 36 69 7 20 121 114 85 85 85 85 85 85 85 85 85 85 85 85 85 | | [0.53; 201.45] [0.25; 118.96] [0.13; 81.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3- 0.19 [0.05; 0.7] 1.22 [0.27; 5.4] 0.37 [0.12; 1.1 1.05 [0.09; 12.2 0.28 [0.01; 5.8 1.89 [0.71; 5.0; 0.39 [0.09; 12.2 0.64 [0.20; 2.00 0.09 [0.00; 1.5- 5.74 [0.30; 110.1 2.29 [0.62; 8.4] 0.49 [0.14; 1.77 0.45 [0.22; 0.9] 1.04 [0.25; 4.33 0.88 [0.29; 2.66] | 4 CI 44] 11] 13] 11] 13] 11] 14] 15] 12] 14] 13] 13] 14] 13] 16] 19] | Odds Ra | atio | 100 |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla B2004 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 Yadav RP2009 González-Rodríguez, F.J200 Choi,S B2011 | 30 25 42 90 610 977 : Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 | ELC Total 27 109 53 21 33 45 21 33 14 74 82 20 132 82 56 62 1 102 85 57 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | 0.99 1.00 1.00 18.4% 100.0% = 0.28 DLC Total 25 85 85 85 84 41 22 27 31 69 87 20 121 114 33 36 69 720 121 114 34 33 69 97 20 121 119 43 44 44 45 55 121 121 121 121 121 121 121 121 121 | $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.37 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.13; 8.2 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.9 [0.71; 5.0; 0.79 [0.33; 1.92; 0.64 [0.00; 1.5; 5.74 [0.30; 110] 2.29 [0.62; 8.4 0.48 [0.14; 1.77 0.45 [0.22; 0.92; 1.04 [0.25; 4.33] 1.04 [0.25; 4.33] | 6 CI 4] 1] 3] 3] 1] 4] 4] 5] 22] 4] 4] 4] 4] 4] 4] 4] 5] 5] 6] 6] 9] 1] 1] 4] 5] 6] 9] 9] 1] 1] 4] 5] 5] 5] 5] 5] 5] 5] 5] 5] 5 | Odds Ra | atio | 100 |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 Yadav RP2009 González–Rodríguez, FJ200 Choi, S B2011 Falor, A.E2012 Panagiotopoulou,I G2012 | 30 25 42 90 610 977 : Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 2 0 13 10 2 5 0 13 10 2 10 10 10 10 10 10 10 10 10 10 | ELC Total 27 109 53 45 21 33 45 21 33 44 74 82 20 132 82 56 36 21 102 57 117 21 | 0 30 0 25 0 44 9 90 649 649 649 111 3 12 2 2 1 1 3 3 12 2 2 1 1 3 3 7 7 6 4 9 7 7 7 7 7 7 7 7 7 7 7 7 7 | 0.99 1.09 1.09 1.84 100.0% = 0.28 DLC Total 25 58 58 58 58 58 58 58 58 58 5 | i 10.36 i 10.36 i 5.43 i 3.22 i 0.64 i 1.30 i 1.2 i 1 ² = 18 Weight 1.8% 0.5% 0.8% 0.3% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.3% | [0.53; 201.45] [0.25; 118.96] [0.22; 118.96] [0.32; 1.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3- 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.13; 8.2- 0.38 [0.07; 5.4] 0.38 [0.07; 5.4] 0.39 [0.09; 12.2 0.28 [0.01; 5.8 1.89 [0.71; 5.4] 0.39 [0.09; 12.2 0.64 [0.20; 2.00 0.09 [0.00; 1.5- 5.74 [0.30; 110.1 2.29 [0.62; 8.4] 0.48 [0.14; 1.77 0.45 [0.22; 0.9] 1.04 [0.25; 4.33 0.88 [0.29; 2.66 0.12 [0.02; 0.7 1.47 [0.13; 16.7 4.74 [0.40; 55.4] | 6 C1 (4] (1] (3] (3] (4] (4] (5] (5] (5] (2) (4] (8] (4] (8] (4] (8] (4] (7) (7) (7) (7) (7) (7) (7) (7) | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 Yadav RP2009 Yadav RP2009 Yadav RP2009 Yadav RP2009 Panagiotopoulou, J G2012 Zhu, Bin2012 Han, I.W2012 Gul R2013 | 30 25 42 90 610 610 777; Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 1 2 5 0 4 5 5 2 2 0 1 3 10 2 5 0 4 5 5 2 2 0 1 3 10 2 5 0 4 5 5 6 2 2 0 1 3 10 2 5 0 4 5 5 6 2 2 0 1 3 10 2 5 0 4 5 6 2 2 0 1 3 10 2 5 0 4 5 6 2 2 0 1 3 10 2 5 0 4 5 6 2 1 2 0 4 5 6 2 1 5 0 4 5 6 2 1 5 0 4 5 6 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1 | ELC Total 27 109 53 45 21 33 31 4 4 20 20 21 33 14 82 20 21 32 82 56 63 6 21 102 57 117 21 34 50 57 102 21 30 30 21 30 30 31 21 32 32 32 32 33 33 34 55 56 57 34 57 57 57 57 57 57 57 57 57 57 57 57 57 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | 0.99 1.09 1.09 1.02 | i 10.36 i 10.36 i 5.43 i 3.22 i 0.64 i 1.30 i 1.2 i 1 ² = 18 Weight 1.8% 0.5% 0.9% 1.4% 0.5% 0.9% 1.2% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.4% 0.5% 0.4% 0.5% 0.4% 0.5% 0.4% 0.5% | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.32; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.13; 8.2- 1.05 [0.13; 8.2- 1.05 [0.13; 8.2- 1.05 [0.13; 8.2- 1.05 [0.13; 8.2- 1.05 [0.13; 8.2- 1.05 [0.03; 1.2- 0.64 [0.20; 2.00 0.09 [0.00; 1.5 1.229 [0.62; 8.4 0.48 [0.14; 1.7' 0.45 [0.22; 0.92; 1.04 [0.25; 4.34 0.88 [0.29; 2.66 0.12 [0.02; 0.7 1.37 [0.13; 15.4] | 6 CI 4] 1] 3] 3] 1] 4] 4] 5] 22] 4] 5] 5] 4] 6] 6] 9] 1] 4] 4] 4] 5] 5] 5] 5] 5 | Odds Ra | atio | |
| 0 | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 Yadav RP2009 González-Rodríguez, F.J200 Choi,S B2011 Falor, A.E2012 Panagiotopoulou,I G2012 Zhu, Bin2012 Han, I.W2012 Gult 2013 | 30 25 42 90 610 610 777; Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 1 2 13 10 2 5 0 4 8 6 9 4 5 2 1 1 1 2 5 1 1 1 1 1 1 1 1 1 1 1 1 1 | ELC Total 27 109 53 45 21 33 14 82 20 20 132 82 56 66 21 102 57 117 21 104 23 34 34 34 30 304 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | 0.99 1.09 1.21 1.14 1.33 1.69 1.21 1.14 1.33 1.66 2.22 2.434 4.344 4.59 1. | i 10.36 i 10.36 i 5.43 i 3.22 i 0.64 i 0.5% 0.3% 0.5% 0.3% 0.5% 0.3% 0.5% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.4% 0.3% 0.5% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.4% 0.3% 0.3% 0.3% 0.3% 0.4% 0.3% 0.3% 0.3% 0.4% 0.4% 0.3% 0.4% 0.3% 0.4% 0.3% 0.4% 0 | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.13; 8.2 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.90 [0.33; 1.92; 0.63 [0.09; 4.2; 0.64 [0.20; 2.00 0.09 [0.00; 1.5; 5.74 [0.30; 110.1] 2.29 [0.62; 8.4 0.48 [0.14; 1.77; 0.48 [0.14; 1.77; 0.48 [0.22; 0.92; 1.04 [0.22; 4.33; 0.88 [0.29; 2.64 0.12 [0.02; 0.7] 1.47 [0.13; 16.7; 4.74 [0.40; 55.4 1.47 [0.40; 55.4 1.30 [0.31; 5.44; 0.71 [0.35; 1.44; 1.4] | 6 CI 44 11] 13] 13] 13] 14] 14] 155 122 14] 13] 14] 13] 14] 13] 166 199 19] 14] 14] 14] 10] 13] 14] 14] 13] 14] 14] 14] 14] 15] 15] 16] 16] 16] 16] 16] 16] 16] 16 | Odds Ra | atio | |
| 0 | Ozkardes AB2014 4 Agrawal R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, A, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 González–Rodríguez, F.J200 Choi,S B2011 Falor, A.E2012 Panagiotopoulou, J G2012 Zhu, Bin2012 Gut 2013 Gutt2013 Gutt2013 Kwon, Y.J2013 | 30 25 42 90 610 610 777; Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 1 2 1 1 2 5 0 4 8 6 9 4 5 2 1 1 1 2 5 1 1 1 1 2 5 1 1 1 1 1 1 1 1 1 1 1 1 1 | ELC Total 27 109 53 45 21 33 45 21 33 14 74 82 20 132 82 56 36 36 21 102 57 71 117 21 34 304 304 33 | 0 30 0 30 0 44 9 90 649 649 649 649 649 649 11 3 12 2 11 3 12 2 11 3 12 2 11 3 12 2 11 3 12 2 11 3 12 2 11 3 3 7 7 0 0 4 4 4 12 12 12 12 12 12 12 12 12 12 | 0.99 1.00 1.00 1.84 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 100.07 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3- 0.19 [0.05; 0.7 1.22 [0.27; 5.4' 0.37 [0.12; 1.1 1.05 [0.03; 12.2 0.28 [0.01; 5.8 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.93 [0.09; 12.2 0.64 [0.20; 2.00 0.09 [0.00; 1.5- 5.74 [0.30; 110.1 2.29 [0.62; 8.4] 0.64 [0.22; 0.9] 1.04 [0.25; 4.33 0.88 [0.29; 2.66 0.12 [0.02; 0.7 1.47 [0.13; 16.7 4.74 [0.40; 55.4 1.30 [0.31; 5.44' 0.71 [0.35; 1.44' 3.72 [0.39; 35.4 | 6 C1 (4] (1] (3] (3] (4] (4] (5] (5) (2) (4] (8] (4] (8] (8] (4] (8] (8] (9] (1] (6] (6] (6] (6] (6] (7) (7) (7) (7) (7) (7) (7) (7) | Odds Ra | atio | |
| 0 | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T. C2008 Macafee DA2009 Yadav RP2009 Yadav RP2009 Yadav RP2009 Yadav RP2009 Yadav RP2009 Panagiotopoulou, J G2012 Zhu, Bin2012 Han, I.W2012 Gul R2013 Gutz013 Kwon, Y.J2013 Ozkardes AB2014 | 30 25 42 90 610 610 777; Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 1 2 5 14 4 5 | ELC Total 27 109 53 45 21 33 31 4 74 82 20 20 20 31 33 45 21 33 34 74 82 20 20 21 33 45 57 1102 57 71102 132 82 53 63 6 21 30 30 30 30 30 30 30 30 30 30 30 30 30 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | 0.99 1.09 1.09 1.09 1.84 100.0% = 0.28 DLCC Total 255 38 41 12 25 38 41 17 31 16 22 17 31 16 43 41 12 11 11 43 33 6 22 10 10 10 10 10 10 10 10 10 10 | $ \begin{array}{cccc} & 10.36 \\ & 5.43 \\ & 5.43 \\ & 3.22 \\ & 0.64 \\ \end{array} $ | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1] 1.05 [0.13; 8.2; 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.90 [0.00; 1.5; 0.64 [0.20; 2.00] 0.64 [0.20; 2.00] 1.04 [0.25; 4.34] 0.88 [0.29; 2.6] 0.12 [0.02; 0.7] 1.47 [0.13; 16.7] 4.74 [0.40; 55.4] 0.71 [0.35; 1.4] 3.72 [0.39; 35.4] 3.16 [0.69; 249.4] | 6 CI 4] 4] 1] 4] 4] 4] 4] 5] 5] 5] 4] 5] 5 | Odds Ra | atio | |
| B | Ozkardes AB2014 Agraval R2015 Roulin J2016 Khalid2017 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 Yadav RP2009 González-Rodríguez, F.J200 Choi,S B2011 Falor, A.E2012 Panagiotopoulou,I G2012 Zhu, Bin2012 Han, I.W2012 Gut2013 Kwon, Y.J2013 Ozkardes AB2014 Agrawal R2015 | 30 25 42 90 610 610 777; Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 1 2 5 14 4 5 6 | ELC Total 27 109 53 45 21 33 14 82 20 20 132 82 56 66 21 102 25 7 117 21 104 304 33 004 33 004 25 | 0 30 0 30 0 44 9 90 649 649 649 649 649 649 11 3 12 2 11 3 12 2 1 1 3 7 7 7 6 4 1 1 3 7 7 7 6 4 4 1 1 2 2 1 1 3 7 7 7 7 7 7 7 7 7 7 7 7 7 | 0.99 1.09 | $ \begin{array}{cccc} & 10.36 \\ & 5.43 \\ & 5.23 \\ & 0.64 \\ \end{array} \\ \begin{array}{c} & & 3.22 \\ & 0.64 \\ \end{array} \\ \begin{array}{c} & & 3.22 \\ & & 3.22 \\ \end{array} \\ \begin{array}{c} & & & 1.30 \\ & & 5.2\% \\ & & & 1.4\% \\ & & & 4.7\% \\ & & & 0.8\% \\ & & & 4.8\% \\ & & & 1.4\% \\ & & & 4.7\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.1\% \\ & & & 0.1\% \\ & & & 0.1\% \\ & & & 0.1\% \\ & & & 0.2\% \\ & & & 0.2\% \\ & & & 0.4\% \\ & & & 0.2\% \\ & & & 0.4\% \\ & & & 0.2\% \\ & & & 0.4\% \\ & & & 0.2\% \\ \end{array} $ | [0.53; 201.45] [0.25; 118.96] [0.22; 118.99] [0.32; 1.89] [0.33; 81.19] [0.22; 1.89] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3, 0.19 [0.05; 0.7 1.22 [0.27; 5.4; 0.37 [0.12; 1.1 1.05 [0.13; 8.2; 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.89 [0.71; 5.0; 0.79 [0.33; 1.9; 0.63 [0.09; 4.2; 0.64 [0.20; 2.00; 0.09 [0.00; 1.5; 5.74 [0.30; 110.1; 5.0; 0.64 [0.20; 2.00; 0.09 [0.00; 1.5; 5.74 [0.30; 110.1; 5.4; 0.48 [0.14; 1.7% 0.48 [0.2; 4.3; 0.88 [0.29; 2.66; 0.12 [0.00; 0.7; 1.47 [0.13; 16.7; 4.74 [0.40; 55.4; 1.37 [0.39; 35.4; 1.37 [0.39; 35.4; 1.37 [0.39; 35.4; 1.36 [0.66; 20.1] | 6 CI 44] 11] 13] 13] 13] 14] 14] 13] 14] 13] 14] 13] 14] 14] 14] 14] 14] 14] 14] 14 | Odds Ra | atio | |
| D | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 Yadav RP2009 González–Rodríguez, FJ200 Choi, S B2011 Falor, A.E2012 Panagiotopoulou, I G2012 Zhu, Bin2012 Han, LW2012 Gul R2013 Gutt2013 Kwon, Y.J2013 Ozkardes AB2014 Agrawal R2015 Roulin D2016 | 30 25 42 90 610 610 777; Chi | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 1 2 5 14 4 5 | ELC Total 27 109 53 45 21 33 31 4 74 82 20 20 20 31 33 45 21 33 34 74 82 20 20 21 33 45 57 1102 57 71102 132 82 53 63 6 21 30 30 30 30 30 30 30 30 30 30 30 30 30 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | 0.99 1.09 1.09 1.84 100.0% = 0.28 DLCC Total 255 38 41 22 217 7 31 22 25 38 40 121 114 43 36 69 87 70 121 114 43 43 43 43 43 43 43 43 43 4 | i 10.363 i 10.363 i 3.222 i 0.64 i 1.30 i 1.2 i 1 ² = 18 Weight 1.8% i 1 ² = 18 Weight 1.8% 0.5% 1.4% 0.8% 0.2% 0 | [0.53; 201.45] [0.25; 118.96] [0.22; 118.96] [0.38; 11.91] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3; 0.19 [0.05; 0.7 1.22 [0.27; 5.4] 0.37 [0.12; 1.1] 1.05 [0.13; 8.2] 1.03 [0.09; 12.2] 0.28 [0.01; 5.8] 1.89 [0.71; 5.0] 0.79 [0.33; 1.9] 0.63 [0.09; 4.2] 0.64 [0.20; 2.09] 0.64 [0.20; 2.09] 1.04 [0.25; 4.3] 0.88 [0.29; 2.66] 0.12 [0.02; 0.7] 1.47 [0.13; 16.7] 1.47 [0.13; 16.7] 1.47 [0.35; 1.44] 1.30 [0.31; 5.44] 0.71 [0.35; 1.44] 0.71 [0.35; 1.44] 0.71 [0.35; 1.44] 0.71 [0.35; 1.44] 0.73 [0.62; 2.04] 0.71 [0.35; 1.44] 0.71 [0.35; 1.44] 0.71 [0.35; 1.44] 0.73 [0.62; 2.04] 0.74 [0.40; 55.4] 0.75 [0.35] < | 6 C1 44] 11] 13] 13] 13] 14] 14] 15] 12] 12] 14] 18] 14] 13] 16] 16] 16] 16] 16] 16] 17] 16] 16] 17] 18] 18] 19] 19] 19] 10] 10] 10] 11] 12] 12] 13] 13] 13] 13] 13] 13] 13] 13 | Odds Ra | atio | |
| C | Ozkardes AB2014 Agraval R2015 Roulin J2016 Khalid2017 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 Yadav RP2009 González-Rodríguez, F.J200 Choi,S B2011 Falor, A.E2012 Panagiotopoulou,I G2012 Zhu, Bin2012 Han, I.W2012 Gut2013 Kwon, Y.J2013 Ozkardes AB2014 Agrawal R2015 | 30 25 42 90 610 6777 ; Chi Event | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 1 2 5 0 4 8 6 9 4 5 2 2 1 1 1 0 2 5 0 4 8 6 9 4 5 6 2 2 0 1 3 1 0 2 5 0 4 8 6 9 4 5 6 2 2 0 1 3 1 0 2 5 0 4 8 6 9 4 5 6 2 2 0 1 3 1 0 2 5 0 4 8 6 9 4 5 6 2 2 0 1 3 1 0 2 5 0 4 8 6 9 4 5 6 2 1 2 5 0 4 8 6 9 4 5 2 1 2 5 0 4 8 6 9 4 5 2 1 2 5 1 1 1 0 2 5 1 2 1 1 1 1 2 5 1 1 1 1 2 5 1 1 1 1 1 1 1 1 1 1 1 1 1 | ELC Total 27 109 53 45 21 33 45 21 33 14 74 82 20 132 82 56 36 21 102 57 77 21 34 102 57 77 21 34 30 4 33 304 33 304 25 542 | 0 30 0 30 0 44 9 90 649 649 649 111 3 3 12 2 2 1 1 3 3 12 2 2 1 1 3 3 7 7 6 4 4 9 1 1 1 1 1 1 1 1 1 1 1 1 1 | 0.99 1.09 1.09 1.09 1.02 | $ \begin{array}{cccc} & 10.36 \\ & 5.43 \\ & 5.23 \\ & 0.64 \\ \end{array} \\ \begin{array}{c} & & 3.22 \\ & 0.64 \\ \end{array} \\ \begin{array}{c} & & 3.22 \\ & & 3.22 \\ \end{array} \\ \begin{array}{c} & & & 1.30 \\ & & 5.2\% \\ & & & 1.4\% \\ & & & 4.7\% \\ & & & 0.8\% \\ & & & 4.8\% \\ & & & 1.4\% \\ & & & 4.7\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.8\% \\ & & & 0.1\% \\ & & & 0.1\% \\ & & & 0.1\% \\ & & & 0.1\% \\ & & & 0.2\% \\ & & & 0.2\% \\ & & & 0.4\% \\ & & & 0.2\% \\ & & & 0.4\% \\ & & & 0.2\% \\ & & & 0.4\% \\ & & & 0.2\% \\ \end{array} $ | [0.53; 201.45] [0.25; 118.96] [0.22; 118.96] [0.38; 1.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.37 1.14 [0.30; 4.37 0.19 [0.05; 0.7 1.22 [0.27; 5.43 0.37 [0.12; 1.1] 1.05 [0.13; 8.22 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.90 [0.03; 1.9] 0.63 [0.09; 4.2] 0.64 [0.20; 2.00] 0.64 [0.20; 2.00] 0.64 [0.20; 2.09] 0.64 [0.20; 2.09] 0.64 [0.20; 2.09] 0.63 [0.09; 4.3] 0.88 [0.29; 2.64] 0.12 [0.02; 0.7] 1.47 [0.30; 110.1] 2.29 [0.61; 8.4 0.48 [0.29; 2.64] 0.12 [0.02; 0.7] 1.47 [0.30; 110.1] 2.43 [0.31; 5.44] 3.72 [0.39; 35.44] 3.74 [0.40; 55.4] 3.74 [0.30; 1.41] 3.75 [0.66; 20.1] 0.88 [0.27; 2.83] 0.31 [0.09] 1.11 <td>6 CI 4] 4] 1] 4] 4] 4] 4] 4]</td> <td>Odds Ra</td> <td>atio</td> <td></td> | 6 CI 4] 4] 1] 4] 4] 4] 4] 4] | Odds Ra | atio | |
| C | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macalee DA2009 Yadav RP2009 Yadav RP2009 Yadav RP2009 Panagiotopoulou, J G2012 Zhu, Bin2012 Han, LW2012 Guit R2013 Guit2013 Guit2013 Kwon, Y.J2013 Ozkardes AB2014 Agrawal R2015 Roulin D2016 Rajeok, M2016 | 30 25 42 90 610 6777 ; Chi Event | ts 6 3 5 6 2 2 0 13 10 2 5 0 4 8 6 9 4 5 2 1 2 5 14 4 5 6 6 4 | ELC Total 27 109 53 45 21 33 14 82 20 20 20 21 33 14 82 20 20 20 21 33 45 56 66 21 132 82 56 66 21 30 30 304 330 300 25 53 34 30 30 30 30 30 30 30 30 30 30 30 30 30 | $\begin{array}{c} 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | 0.99 1.00 1.00 1.00 1.84 DLC Total 255 85 85 85 85 85 84 11 22 25 85 85 85 85 85 85 85 85 85 85 85 85 85 | i 10.36 i 10.36 i 5.43 i 3.22 i 0.64 i 1.30 i 1.2 i 1 ² = 18 Weight 1.8% 0.5% 0.8% 0.9% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.9% 0.8% 0.9% 0.3% 1.106% 1.16% 0.2% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.3% 0.3% 0.2% 0.3% 0.2% 0.3% 0.3% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.1% 0.1% 0.1% 0.2% 0.1% 0. | [0.53; 201.45] [0.25; 118.96] [0.22; 118.96] [0.38; 11.91] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3; 0.19 [0.05; 0.7 1.22 [0.27; 5.4] 0.37 [0.12; 1.1] 1.05 [0.13; 8.2; 1.03 [0.09; 12.2] 0.28 [0.01; 5.8] 1.89 [0.71; 5.0] 0.63 [0.09; 4.2; 0.64 [0.20; 2.09] 0.64 [0.20; 2.09] 0.63 [0.09; 4.2; 0.64 [0.20; 2.09] 1.48 [0.71; 5.0] 0.79 [0.33; 1.9] 0.63 [0.09; 4.2; 0.64 [0.20; 2.09] 1.04 [0.25; 4.3] 0.88 [0.29; 2.60] 0.12 [0.02; 0.7] 1.47 [0.13; 16.7] 1.30 [0.31; 5.4] 0.71 [0.35; 1.4] 1.30 [0.31; 5.4] 0.71 [0.35; 1.4] 0.71 [0.35; 1.4] 0.73 [0.39; 35.4] 0.31 [0.09; 1.5] 0.31 [0.07; 2.8] 0.31 [0.07; 2.8] | 6 C1 44] 11] 13] 13] 11] 44] 42] 22] 22] 23] 44] 44] 44] 44] 44] 44] 44] 4 | Odds Ra | atio | |
| | Ozkardes AB2014 4 Agrawal R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB204 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafe DA2009 Yadav RP2009 González-Rodríguez, F.J200 Choi, S B2011 Falor, A.E2012 Panagiotopoulou, I G2012 Zhu, Bin2012 Han, I.W2012 Gul R2013 Gutt2013 Gutt2013 Gutt2013 Kwon, Y.J2013 Ozkardes AB2014 Agrawal R2015 Roulin D2016 Rajeok, M2016 Khalid2017 Davoodabadi2020 Wu, Hongsheng2021 | 30 25 42 90 610 610 777; Chi Event | $\begin{array}{c} \textbf{ts} \\ \hline 6 \\ 3 \\ 5 \\ 6 \\ 2 \\ 2 \\ 0 \\ 13 \\ 10 \\ 2 \\ 5 \\ 0 \\ 4 \\ 8 \\ 6 \\ 9 \\ 4 \\ 5 \\ 2 \\ 1 \\ 2 \\ 5 \\ 14 \\ 4 \\ 5 \\ 6 \\ 6 \\ 4 \\ 19 \\ 4 \\ 27 \\ \end{array}$ | ELC Total 27 109 53 45 21 33 14 82 20 20 20 20 21 33 14 82 20 20 20 21 33 45 21 33 31 4 21 33 31 4 22 56 66 21 30 25 77 21 30 30 45 57 21 33 31 21 33 31 21 22 33 31 22 21 33 31 22 21 33 31 24 55 21 33 31 24 55 21 33 31 24 55 21 33 31 24 55 21 33 31 24 55 21 33 31 24 55 21 33 31 24 55 21 33 31 24 55 21 33 31 24 55 21 33 31 24 55 24 20 20 20 20 20 20 20 20 20 20 20 20 20 | $\begin{array}{c} 0 & 30 \\ 0 & 30 \\ 0 & 25 \\ 0 & 44 \\ 9 & 90 \\ \hline \\ $ | 0.99 1.09 1.09 1.09 1.84 100.0% = 0.28 DLCC Total 255 358 411 225 358 411 17 31 16 22 17 31 17 31 16 22 17 31 17 31 11 43 43 41 11 11 11 11 11 11 11 11 11 | i 10.36 i 10.36 i 5.43 i 3.22 i 0.64 i 1.30 i 1.20 i 1.20 i 1.20 i 1.20 i 1.4% 1.4% 0.5% 0.7% | [0.53; 201.45] [0.25; 118.96] [0.22; 118.96] [0.38; 1.19] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.37 0.19 [0.05; 0.7 1.22 [0.27; 5.43 0.37 [0.12; 1.1] 1.05 [0.13; 8.22 1.03 [0.09; 12.2 0.28 [0.01; 5.8 1.90 [0.03; 1.9] 0.63 [0.09; 4.2] 0.64 [0.20; 2.00] 0.64 [0.20; 2.00] 0.64 [0.20; 2.00] 0.64 [0.20; 2.09] 1.04 [0.25; 4.30] 0.88 [0.29; 2.66] 0.12 [0.02; 0.7] 1.47 [0.13; 16.7] 4.74 [0.40; 55.4] 3.012 [0.02; 0.7] 1.47 [0.35; 1.44] 3.72 [0.39; 35.4] 3.16 [0.66; 249.4] 3.63 [0.66; 249.4] 3.63 [0.66; 249.4] 3.63 [0.66; 249.4] 3.63 [0.66; 249.4] 3.63 [0.66; 249.4] 3.63 [0.69; 1.11] 0.83 [0.09; 1.51] 0.72 [8.30] | 6 CI 4 4 11 3 13 4 4 4 4 4 4 5 5 2 2 4 4 8 8 3 3 4 4 4 4 4 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 | Odds Ra | atio | 100 |
| | Ozkardes AB2014 4 Agraval R2015 2 Roulin J2016 1 Khalid2017 6 Total (95% CI) Heterogeneity: Tau ² = 0.2 Study Lo, C.M1996 Garber, S.M1997 Lai, P.B1998 Lo, C. M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Stevens, K.A2006 Al-Mulhim2008 Chang, T C2008 Macafee DA2009 Yadav RP2009 González–Rodríguez, FJ200 Choi, S B2011 Falor, A.E2012 Panagiotopoulou, I G2012 Zhu, Bin2012 Han, I.W2012 Gul R2013 Gutt2013 Kwon, Y.J2013 Ozkardes AB2014 Agraval R2015 Roulin D2016 Rajeok, M2016 Khalid2017 Davoodabadi2020 | 30 25 42 90 610 610 777; Chi Event | $\begin{array}{c} \textbf{ts} \\ \hline 6 \\ 3 \\ 5 \\ 6 \\ 2 \\ 2 \\ 0 \\ 13 \\ 10 \\ 2 \\ 5 \\ 0 \\ 4 \\ 8 \\ 6 \\ 9 \\ 4 \\ 5 \\ 2 \\ 1 \\ 2 \\ 5 \\ 14 \\ 4 \\ 5 \\ 6 \\ 6 \\ 4 \\ 19 \\ 4 \end{array}$ | ELC Total 27 109 53 45 21 33 45 21 33 44 74 82 20 132 82 66 36 21 132 82 65 36 21 102 57 71 17 21 30 304 303 305 22 31 90 0 | 0 30 0 30 0 44 9 90 649 649 649 111 3 3 12 2 1 1 3 3 12 2 2 1 1 3 3 7 7 6 4 4 10 7 7 7 7 7 7 10 10 10 10 10 10 10 10 10 10 | 0.99 1.09 1.09 1.09 1.84 100.0% = 0.28 DLCC Total 255 358 411 225 358 411 17 31 16 22 17 31 17 31 16 22 17 31 17 31 11 43 43 41 11 11 11 11 11 11 11 11 11 | i 10.36 i 10.36 i 5.43 i 3.22 i 0.64 i 1.30 i 1.2 i 1 ² = 18 Weight 1.8% 0.5% 0.8% 0.9% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.9% 0.8% 0.9% 0.3% 1.106% 1.16% 0.2% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.3% 0.3% 0.2% 0.3% 0.2% 0.3% 0.3% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.3% 0.2% 0.1% 0.1% 0.1% 0.2% 0.1% 0. | [0.53; 201.45] [0.25; 118.96] [0.22; 118.96] [0.38; 11.91] [0.22; 1.89] [0.89; 1.91] % Odds Ratio MH, Fixed, 95% 1.14 [0.30; 4.3; 0.19 [0.05; 0.7 1.22 [0.27; 5.4] 0.37 [0.12; 1.1] 1.05 [0.13; 8.2; 1.03 [0.09; 12.2] 0.28 [0.01; 5.8] 1.89 [0.71; 5.0] 0.63 [0.09; 4.2; 0.64 [0.20; 2.09] 0.64 [0.20; 2.09] 0.63 [0.09; 4.2; 0.64 [0.20; 2.09] 1.48 [0.71; 5.0] 0.79 [0.33; 1.9] 0.63 [0.09; 4.2; 0.64 [0.20; 2.09] 1.04 [0.25; 4.3] 0.88 [0.29; 2.60] 0.12 [0.02; 0.7] 1.47 [0.13; 16.7] 1.30 [0.31; 5.4] 0.71 [0.35; 1.4] 1.30 [0.31; 5.4] 0.71 [0.35; 1.4] 0.71 [0.35; 1.4] 0.73 [0.39; 35.4] 0.31 [0.09; 1.5] 0.31 [0.07; 2.8] 0.31 [0.07; 2.8] | 6 CI 4 4 11 3 13 4 4 4 4 4 4 5 5 2 2 4 4 8 8 3 3 4 4 4 4 4 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 | Odds Ra | atio | |

Forest plot of primary outcomes between ELC and DLC. (A).Conversion rate; (B).Intraoperative complications; (C).Postoperative complications. Green squares represent the point estimates of the treatment effect OR, with 95% CI indicated by horizontal bars. Blue diamonds represent the summary estimate from the pooled studies with 95% CI using common fixed models.

| Study | ELC Mean SD Tota | DLC Mean SD To | tal Weight | Mean Difference IV, Random, 95% Cl | Mean Difference IV, Random, 95% CI |
|---|--|---|--|---|---------------------------------------|
| Garber, S. M1997 | 100.00 37.00 109 | | | | 1 |
| Lai, P.B1998 | 122.80 36.00 53 | | 85 3.5% 38 3.3% | -20.00 [-33.60; -6.40] 16.20 [0.88; 31.52] | |
| Lo, C.M1998 Chandler CF2000 | 135.00 73.50 4: 115.00 8.00 2 | | 41 2.3% 22 4.2% | 30.00 [3.21; 56.79] -10.00 [-15.73; -4.27] | |
| Bhattacharya2002 | 78.00 15.75 33 | 91.75 18.75 | 17 3.8% | -13.75 [-24.16; -3.34] | |
| Madan, A K2002 Serralta, A.S2003 | 73.00 21.00 14 74.70 27.90 82 | | | -19.00 [-35.78; -2.22] -18.70 [-29.38; -8.02] | |
| Johansson, M2003 | 98.00 30.00 74 | | | -2.00 [-14.63; 10.63] | |
| Kolla SB2004 | 104.00 15.00 20 | | 20 3.8% | 11.00 [0.73; 21.27] | |
| Stevens, K. A2006 Stevens, K. A2006 | 92.00 41.00 132 105.00 49.50 82 | | 21 3.8% 14 3.4% | -3.00 [-12.99; 6.99] -21.00 [-35.96; -6.04] | |
| Yadav RP2009 | 94.76 35.79 2 | | 22 3.1% | 33.09 [15.89; 50.29] | |
| González–Rodríguez, F.J2009 Chang, T C2009 | 79.80 31.00 102 109.00 38.00 56 | | 34 4.1% 33 3.5% | -5.70 [-12.56; 1.16] 32.00 [18.67; 45.33] | — |
| Choi, S B2011 | 98.00 23.20 5' | 107.00 35.60 | 59 3.8% | -9.00 [-19.90; 1.90] | , |
| Zhu, Bin2012 Han, I. W2012 | 44.10 5.31 34 79.30 25.30 21 | | 99 4.3% - 46 3.2% | -22.30 [-24.18; -20.42 25.60 [8.62; 42.58] | |
| Gul R2013 | 98.83 12.40 30 75.50 29.30 33 | 80.67 14.50 | 30 4.1% 28 3.6% | 18.16 [11.33; 24.99] | |
| Kwon, Y.J2013 Ozkardes AB2014 | 75.50 29.30 31 67.00 28.51 30 | 71.33 24.06 | 28 3.6% 30 3.5% | 4.10 [-8.32; 16.52] -4.33 [-17.68; 9.02] | _ |
| Agrawal R2015 Roulin D2016 | 69.40 29.59 2: 91.00 15.00 42 | | 25 3.5% 44 4.1% | 3.00 [-10.18; 16.18] 3.00 [-3.77; 9.77] | - |
| Rajcok, M2016 | 75.90 23.30 3 | 90.00 32.50 | 31 3.5% | -14.10 [-28.18; -0.02] | |
| Khalid2017 Davoodabadi2020 | 64.32 12.30 90 83.70 7.49 104 | | 90 4.3% 04 4.3% | 6.08 [2.31; 9.85] 1.97 [-0.50; 4.44] | |
| Wu, Hongsheng2021 | 82.48 25.67 1503 | | | 0.33 [-1.51; 2.17] | 4 |
| Isil, R.G2021 | 60.00 23.50 8 | 50.50 25.60 | 88 4.1% | 9.50 [2.24; 16.76] | - |
| Total (95% CI) Heterogeneity: Tau ² – 202.6737 | 293 2 ; Chi ² = 598.84, df = 26 | | 52 100.0% | 0.46 [-5.35; 6.27] | -40 -20 0 20 40 |
| Study | ELC Mean SD Total | DLC Mean SD Total | | an Difference andom, 95% CI | Mean Difference IV, Random, 95% CI |
| Lo, C.M1996 | 5.10 3.70 27 | 2.50 3.40 25 | | [0.67; 4.53] | _ |
| Lai, P.B1998 Lo, C.M1998 | 4.80 3.75 53 4.00 2.00 45 | 3.00 2.25 52 3.00 1.20 41 | | [0.62; 2.98] [0.31; 1.69] | |
| Chandler CF2000 | 3.30 0.80 21 | 3.20 1.00 22 | 5.4% 0.10 | [-0.44; 0.64] | _ * |
| Madan,A K2002 Bhattacharya2002 | 1.20 0.60 14 1.25 1.00 33 | 3.40 1.10 31 1.50 0.50 17 | | [-2.70; -1.70] 5 [-0.67; 0.17] | |
| Serralta, A.S2003 Kolla SB2004 | 5.30 4.50 82 3.20 8.00 20 | 3.60 3.40 87 2.30 2.00 20 | | [0.49; 2.91] [-2.71; 4.51] | |
| Akyürek, N2005 | 1.58 0.72 31 | 1.66 0.72 30 | 5.5% -0.08 | 8 [-0.44; 0.28] | ÷ - |
| Al-Mulhim2008 Macafee DA2009 | 3.40 2.20 82 2.20 0.80 36 | 4.00 2.70 114 1.20 0.60 36 | | [-1.29; 0.09] [0.67; 1.33] | |
| González-Rodríguez, F.J2009 | 6.50 5.00 102 | 9.50 4.00 434 | 5.0% -3.00 | [-4.04; -1.96] | •- ⁻ _ |
| Chang, T C2009 Choi, S B2011 | 4.50 4.40 56 5.30 1.20 57 | 2.60 1.50 33 5.90 1.30 59 | | [0.64; 3.16] [-1.06; -0.14] | |
| Zhu, Bin2012 | 6.50 1.31 34 | 6.67 0.73 99 | 5.5% -0.1 | [-0.63; 0.29] | - |
| Han, I.W2012 Kwon, Y.J2013 | 5.00 3.70 21 4.20 2.50 33 | 4.10 6.70 46 3.30 1.60 28 | | [-1.60; 3.40] [-0.14; 1.94] | |
| Agrawal R2015 | | 3.20 0.95 25 | 5.4% -0.20 | 0 [-0.74; 0.34] | _ + |
| | 3.00 1.00 25 | | | [-3.07; -2.35] | <u> </u> |
| Khalid2017 | 1.67 0.89 90 | 4.38 1.48 90 5.74 2.43 1644 | | [-3.04; -2.72] | + |
| | 1.67 0.89 90 2.86 2.22 1503 2365 | 5.74 2.43 1644 2933 | | [-3.04; -2.72] [-0.83; 0.62] | ■ |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; | $\begin{array}{c} 1.67 0.89 90 \\ 2.86 2.22 1503 \\ \end{array}$ $\begin{array}{c} \textbf{2365} \\ \text{Chi}^2 = 936.06, \text{df} = 19 (\text{P}) \\ \end{array}$ $\begin{array}{c} \textbf{ELC} \end{array}$ | 5.74 2.43 1644 2933 < 0.01); 1 ² = 98% DLC | 5.6% -2.88 | [-0.83; 0.62] -4 Jean Difference | -2 0 2 4 Mean Difference |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; ; | $\frac{1.67 \ 0.89 \ 90}{2.86 \ 2.22 \ 1503}$ $\frac{2365}{Chi^2 = 936.06, df - 19 \ (P}$ $\frac{ELC}{Mean \ SD \ Total}$ | 5.74 2.43 1644 2933 < 0.01); I ² = 98% <u>DLC</u> <u>Mean SD Total</u> | 5.6% -2.88 100.0% -0.11 Weight IV | [-0.83; 0.62] -4 Aean Difference Random, 95% CI | |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; · Study Lo, C.M1996 | $\frac{1.67 \ 0.89 \ 90}{2.86 \ 2.22 \ 1503}$ $\frac{2365}{Chi^2 = 936.06, df = 19 \ (P)}$ $\frac{ELC}{Mean \ 5D \ Total}$ $6.70 \ 4.10 \ 27$ | $5.74 2.43 1644$ 2933 $< 0.01 ; I^{2} = 98\%$ $\frac{DLC}{Mean SD Total}$ $15.10 11.10 25$ | 5.6% -2.88 100.0% -0.13 Weight IV 2.0% -8. | [-0.83; 0.62] -4 Aean Difference Random, 95% CI 40 [-13.02; -3.78] | Mean Difference |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; ; Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \hline \\ \begin{array}{c} 2365 \\ \hline \\ Chi^2 = 936.06, df = 19 & (P \\ \hline \hline \\ \hline \hline \\ $ | 5.74 2.43 1644 2933 < 0.01); I ² = 98% Mean SD Total 15.10 11.10 2.40 11.00 5.40 41 | 5.6% -2.88 100.0% -0.13 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. | [-0.83; 0.62] -4 Alean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] | Mean Difference |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} \textbf{2365} \\ \textbf{Chi}^2 = 936.06, \ df = 19 & (P \\ \hline \hline \textbf{Mean} & \textbf{SD} & \textbf{Total} \\ \hline \hline \textbf{6.70} & 4.10 & 27 \\ 7.60 & 3.60 & 53 \\ 6.00 & 3.20 & 45 \\ 5.40 & 0.60 & 21 \\ \end{array}$ | 5.74 2.43 1644 2933 < 0.01): 1 ² = 98% DLC Mean SD Total 15.10 11.10 25 11.60 3.40 341 1.00 5.40 41 7.10 0.50 22 | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -1. | [-0.83; 0.62] -4 Ican Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] | Mean Difference |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; / Study Lo, C.M1996 Lai, P.B1998 Chandler CF2000 Bhattacharya2002 Madan,A K2002 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} \textbf{2365} \\ \textbf{Chi}^2 = 936.06, \ df = 19 & (P \\ \hline \hline \textbf{Mean} & \textbf{SD} & \textbf{Total} \\ \hline \hline \textbf{6.70} & 4.10 & 27 \\ 7.60 & 3.60 & 53 \\ 6.00 & 3.20 & 45 \\ 5.40 & 0.60 & 2.1 \\ 8.00 & 2.25 & 33 \\ 2.10 & 0.70 & 14 \\ \end{array}$ | 5.74 2.43 1644 2933 < 0.01); I ² = 98% DEC Mean SD Total 15.10 11.10 25 11.60 3.40 34 11.00 5.540 41 1.7.10 0.50 22 7.75 0.75 17 4.40 1.60 31 | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -1. 3.4% -2. | [-0.83; 0.62] -4 Aean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-5.45; -2.55] 00 [-5.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] | Mean Difference |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; ; Study Lo, C.M1996 Lo, C.M1998 Lo, C.M1998 Lo, C.M1998 Lo, C.M1998 Lo, C.M1998 Johanson, M2003 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array}$ | $\begin{array}{cccc} 5.74 & 2.43 & 1644 \\ & & & & & \\ 2933 \\ < 0.01); \ I^2 - 98\% \\ \hline \\ \hline \hline \\ \hline \hline \\ \hline \hline \\ \hline \\ \hline \\ \hline \\ \hline $ | 5.6% -2.88 100.0% -0.13 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -1. 3.4% 0. 3.4% 0. 3.4% -2. 3.4% -2. | [-0.83; 0.62] -4 Hean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] | Mean Difference |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; (Study Lo, C.M1996 Lai, P.J1998 Lo, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serrata, A.S2003 Kolla SB2004 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ $ | 5.74 2.43 1644 2933 < 0.01); I ² = 98% DLC Mean 5D Total 15.10 11.10 25 11.60 3.40 38 11.00 5.40 41 10.50 22 7.75 0.75 17 4.40 1.60 31 8.00 2.50 69 13.40 5.80 89 13.40 5.80 89 14.40 5.80 89 14.40 5.80 89 15.40 5.80 89 15. | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -1. 3.4% 0. 3.4% -2. 3.4% -3. 3.2% -7. 2.0% -7. | [-0.83; 0.62] -4 Aean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-10.62; -1.38] | Mean Difference |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; ; Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Akyürek, N2005 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array}$ | $\begin{array}{c ccccc} 5.74 & 2.43 & 1644 \\ & & & & & \\ \hline \begin{array}{c} & & & & \\ \hline \hline Mcan & SD & Total \\ \hline 15.10 & 11.10 & 25 \\ 11.60 & 3.40 & 38 \\ 11.00 & 5.40 & 41 \\ 1.710 & 0.50 & 22 \\ 7.75 & 0.75 & 1.77 \\ 4.40 & 1.60 & 31 \\ 8.00 & 2.50 & 69 \\ 13.40 & 5.80 & 87 \\ 10.10 & 6.10 & 20 \\ 15.20 & 6.20 & 30 \end{array}$ | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -8. 3.5% -1. 3.4% 0. 3.4% 0. 3.4% -2. 3.4% -2. 3.4% -7. 2.0% -6. 2.9% -6. | [-0.83; 0.62] -4 Hean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-10.62; -1.38] 00 [-12.31; -7.49] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; ; Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serrata, A.S2004 Akyürek, N2005 Stevens, K. A2006 Al-Mulhim2008 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ $ | $\begin{array}{cccc} 5.74 & 2.43 & 1644 \\ & & & & & & \\ & & & & & \\ & & & & &$ | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -1. 3.4% 0. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.5% -1. 3.3% -1. 3.3% -1. 3.3% -1. 3.5% -1. 3.3% -1. 3.3% -1. 3.3% -1. 3.5% -1. | [-0.83; 0.62] -4 dean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.23; -1.38] 90 [-1.23; -7.49] 00 [-1.25; -0.75] 10 [-8.19; -6.01] | Mean Difference |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhatucharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2.004 Akyärek, N2005 Stevens, K. A2006 Al-Multim2008 Macafee DA2009 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ Chi^2 = 936.06, df = 19 \\ \hline \\ $ | 5.74 2.43 1644 2933 2933 SD Total 15.10 11.10 25 11.60 3.40 34 7.10 0.50 22 7.55 0.75 17 4.40 1.60 31 8.00 2.50 68 10.10 6.10 20 15.20 6.20 30 3.00 1.00 121 12.20 5.30 144 | 5.6% -2.8% 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -2. 3.5% -1. 3.4% 0. 3.4% 0. 3.4% 0. 3.4% 0. 3.4% 0. 3.4% 0. 3.4% 0. 3.5% -1. 3.3% -7. 2.0% 6. 2.9% 6. 2.9% 6. 3.5% -1. 3.3% 7. 3.5% -1. 3.3% 7. 3.5% 7. 3.5% 7. 3.5% 7. 3.5% 7. 3.5% 7. 3.5% 7. 3.5% 7. 3.5% 7. 3.5% 7. 5% 7 | [-0.83; 0.62] -4 Aean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-5.45; -2.55] 00 [-5.45; -2.55] 00 [-5.45; -2.55] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.25; -6.23] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-0.65] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; ; Study Lo, C.M1996 Lai, P.B1998 La, C.M1996 Lai, P.B1998 La, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Akyärek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafee DA2009 Yadav RP2009 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ Chi^2 = 936.06, df - 19 & (P \\ \hline \\ $ | $\begin{array}{c cccc} 5.74 & 2.43 & 1644 \\ & & & & & \\ & & & & & \\ \hline \\ \hline \hline Mean & SD & & & \\ \hline \\ \hline \\ \hline \\ 15.10 & 11.10 & 25 \\ 11.60 & 3.40 & 341 \\ 7.10 & 0.50 & 22 \\ 7.75 & 0.75 & 17 \\ 4.40 & 1.60 & 31 \\ 8.00 & 2.50 & 61 \\ 7.17 & 0.50 & 22 \\ 1.40 & 0.50 & 11 \\ 1.20 & 5.00 & 114 \\ 6.00 & 1.50 & 36 \\ 7.23 & 1.63 & 32 \\ 7.55 & 1.74 \\ 1.40 & 1.60 & 341 \\ 1.40 & 1.50 & 36 \\ 1.40 & 1.50 $ | 5.6% -2.8% 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -1. 3.4% -2. 3.4% -3. 3.2% -4. 3.4% -2. 3.4% -1. 3.3% -1. 3.3% -1. 3.3% -1. 3.3% -1. 3.3% -1. 3.4% 0. 3.4% 0 | [-0.83; 0.62] -4 dean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.23; -7.49] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-0.65; 0.65] 90 [-3.82; -1.98] 90 [-1.437; -1.33] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Akyürek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafee DA2009 Yadav RP2009 González-Rodriguez, FJ2009 Chang, T C2009 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ \mbox{Chi}^2 = 936.06, \ df = 19 & (P \\ \hline \\ \hline \hline \mbox{Mcan} & \mbox{SD} & \mbox{Total} \\ \hline \\ \hline \hline \\ \mbox{Chi}^2 = 936.00, \ df = 10 & (P \\ \hline \\ \hline \\ \hline \\ \mbox{Mcan} & \mbox{SD} & \mbox{Total} \\ \hline \\ \hline \\ \mbox{Chi}^2 = 936.00, \ df = 10 & (P \\ \hline \\ \hline \\ \hline \\ \mbox{Mcan} & \mbox{SD} & \mbox{Total} \\ \hline \\ \hline \\ \mbox{Chi}^2 = 936.00, \ df = 10 & (P \\ \hline \\ \hline \\ \mbox{Mcan} & \mbox{SD} & \mbox{Total} \\ \hline \\ \hline \\ \mbox{Chi}^2 = 936.00, \ df = 10 & (P \\ \hline \\ \hline \\ \mbox{Mcan} & \mbox{SD} & \mbox{Total} \\ \hline \\ \hline \\ \mbox{Chi}^2 = 936.00, \ df \\ \mbox{Mcan} & \mbox{SD} & \mbox{Total} \\ \hline \\ \mbox{Chi}^2 = 936.00, \ df \\ \mbox{Mcan} & \mbox{SD} & \mbox{Total} \\ \hline \\ \mbox{Mcan} & \mbox{SD} & \mbox{Total} \\ \hline \\ \mbox{Mcan} & \mbox{SD} & \mbox{Total} \\ \mbox{Mcan} & \mbox{Mcan} & \mbox{SD} \\ \mbox{Mcan} & \mbox{SD} & \mbox{Mcan} \\ \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} \\ \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} \\ \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} \\ \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} \\ \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} \\ \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} \\ \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} & \mbox{Mcan} \\ \mbox{Mcan} & \mbox{Mcan} & \mb$ | $\begin{array}{c cccc} 5.74 & 2.43 & 1644 \\ \hline & & & & & & & \\ \hline & & & & & & \\ \hline & & & &$ | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -4. 3.5% -4. 3.5% -2. 3.4% -2. 3.4% -3. 3.2% -6. 2.9% -9. 3.5% -1. 3.3% -7. 3.4% -2. 3.5% -1. 3.3% -7. 3.4% -2. 3.4% -2. 3.5% -7. 3.4% -7. 3.5% -7. | [-0.83; 0.62] 4 Aean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-3.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-3.68; -2.32] 80 [-9.37; -6.23] 90 [-1.63] -2.77; -1.63] 90 [-1.63; -0.75] 10 [-8.19; -6.01] 90 [-3.65; -0.65] 90 [-3.82; -1.38] 90 [-1.447; -11.33] 90 [-1.30] [-3.05] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhatucharya2002 Madan, A K2002 Johansson, M2003 Serratta, A.S2003 Kolla SB2004 Akyūrek, N2005 Stevens, K. A2006 Al-Multim2008 Macafee DA2009 Yadav RP2009 Conzález-Rodriguez, FJ2009 Chang, T C2009 Chai, S B2011 Zhu, Bin2012 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ Chi^2 = 936.06, df = 19 \\ \hline \\ $ | 5.74 2.43 1644 2933 < 0.01); I ² = 98% blue blue blue blue 1.160 3.40 3.60 1.100 5.50 6.20 3.11 3.40 5.80 6.87 10.10 6.10 200 15.20 6.20 3.03 3.00 1.00 121 12.20 5.30 114 6.00 1.50 36 7.33 1.63 22 27.53 1.63 22 20.50 1.100 5.10 36 7.23 1.63 22 20.50 1.60 434 7.80 4.80 33 31.1.30 3.60 59 12.10 1.25 99 9 9 9 9 | 5.6% -2.8% 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4 3.1% -2 3.5% -1. 3.4% -2 3.4% -3 3.2% -7 2.0% -6. 2.9% -9, 3.5% -1. 3.3% -7 3.4% -2 3.5% -1. 3.3% -7 3.4% -2 3.1% -3 3.3% -4 3.4% -4 3.4% -4 | [-0.83; 0.62] -4 Aean Difference Random, 95% CI 00 [-3.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.23; -7.49] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-0.65; 0.65] 90 [-3.82; -1.98] 90 [-4.47; -1.13] 30 [-5.30; -1.30] 50 [-5.57; -3.43] 60 [-5.13; -4.07] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; / Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhatucharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SB2004 Akyürek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafee DA2009 Yadav RP2009 González–Rodriguez, FJ2009 Choi, S B2011 Zhu, Bin2012 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ \ \ \ \ \ \ \ \ \ \ \ \ \$ | $\begin{array}{c cccc} 5.74 & 2.43 & 1644 \\ & & & & & & & & \\ \hline & & & & & & & \\ \hline & & & &$ | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -1. 3.4% -2. 3.4% -2. 3.4% -3. 3.2% -7. 2.0% -6. 2.9% -9. 3.5% -7. 3.4% -2. 3.5% -7. 3.4% -2. 3.5% -7. 3.5% -7. 5% -7. | [-0.83; 0.62] 4 dean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.297; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-3.82; -1.98] 90 [-3.447; -1.133] 50 [-5.57; -3.43] 60 [-5.13; -4.07] 00 [-0.83] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; · Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SE2004 Akyürek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafee DA2009 GonzálezRodríguez, FJ2009 Chang, T C2009 GonzálezRodríguez, FJ2009 Chang, T C2009 Chang, T C2009 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ \mbox{Chi}^2 = 936.06, df = 19 & (P \\ \hline \\ $ | $\begin{array}{c cccc} 5.74 & 2.43 & 1644 \\ & & & & & & & & \\ \hline & & & & & & & \\ \hline & & & &$ | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -4. 3.5% -3. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.5% -7. 3.4% 0. 3.3% -4. 3.3% -4. 3.4% 0. 3.5% -3. 2.5% -3. 2.5% -3. 2.5% -3. 3.5% -3. 3 | [-0.83; 0.62] -4 dean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-3.68; -0.75] 10 [-8.19; -6.01] 00 [-3.62; -0.75] 10 [-5.37; -3.43] 60 [-5.37; -3.43] 60 [-5.13; -4.07] 00 [-0.83] 00 [-3.41; -2.59] 00 [-7.21; -0.59] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; ; Study Lo, C.M1996 Lai, P.B1998 La, C.M1996 Lai, P.B1998 La, C.M1998 Chandler CF2000 Bhatucharya2002 Madan, A K2002 Johansson, M2003 Serralta, A S2003 Kolla SB2004 Akyürek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafee DA2009 González-Rodríguez, FJ2009 Choi, S B2011 Zhu, Bin2012 Panagiotopoulou2012 Falor, A.E2012 Han, I.W2012 Gui R2013 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ \ \ \ \ \ \ \ \ \ \ \ \ \$ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | 5.6% -2.8% 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -3. 3.4% -2. 3.4% -3. 3.2% -1. 3.4% -2. 3.4% -3. 3.2% -1. 3.3% -1. 3.3% -1. 3.3% -1. 3.3% -1. 3.3% -2. 3.3% -1. 3.3% -2. 3.3% -3. 3.3% -3. 3.3% -3. 3.3% -3. 3.3% -3. 3.5% -3. 3.5% -3. 3.5% -3. 3.5% -3. 3.5% -3. 3.5% -3. 3.5% -3. 3.5% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.5% | [-0.83; 0.62] -4 dean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-1.2.31; -7.49] 00 [-1.2.5; -0.75] 10 [-1.38] 20 [-1.2.31; -7.49] 00 [-1.2.5; -0.75] 10 [-8.19; -6.01] 00 [-0.65; 0.65] 90 [-3.82; -1.98] 90 [-3.82; -1.98] 90 [-3.82; -1.98] 90 [-3.13; -4.07] 00 [-0.83] 00 [-3.44; -2.59] 30 [-5.57; -3.43] 30 [-5.59] 31 [-6.05] 90 [-7.21; -0.59] 33 [-6.01] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; · Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolla SE2004 Akyürek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafee DA2009 GonzálezRodríguez, FJ2009 Chang, T C2009 GonzálezRodríguez, FJ2009 Chang, T C2009 Chang, T C2009 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ \mbox{Chi}^2 = 936.06, df = 19 & (P \\ \hline \\ $ | $\begin{array}{c cccc} 5.74 & 2.43 & 1644 \\ & & & & & & & & \\ \hline & & & & & & & \\ \hline & & & &$ | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -5. 3.5% -1. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.5% -7. 3.3% -4. 3.3% -4. 3.4% -2. 3.5% -3. 3.5% -3. 2.5% -3. 3.5% -3. | [-0.83; 0.62] -4 dean Difference: Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.43] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-3.63; -1.98] 90 [-1.447; -11.33] 30 [-5.57; -3.43] 60 [-5.13; -4.07] 00 [-0.83] 00 [-3.41; -2.59] 33 [-6.01; -4.65] 33 [-6.01; -4.65] 33 [-6.01; -4.65] 34 [-5.19; -1.61] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; / Study Lo, C.M1996 Lai, P.B1998 La, C.M1996 Lai, P.B1998 La, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Seraita, A.S2003 Kolla SB2004 Akyärek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafee DA2009 Yadav RP2009 González-Rodriguez, FJ2009 Chaig, T C2009 Chaig, T C2012 Falor, A.E.2012 Han, I.W2012 Guil R2013 Guit2013 Kwon, YJ2013 Gomes, RM2013 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 \\ \hline \\ \mbox{cm} & cm$ | $\begin{array}{c cccc} 5.74 & 2.43 & 1644 \\ & & & & & & & & \\ \hline & & & & & & & \\ \hline Mean & SD & & & & \\ \hline I1.00 & 5.40 & 411 \\ \hline 7.10 & 0.50 & 222 \\ 7.55 & 0.75 & 1.75 \\ 11.00 & 5.40 & 411 \\ \hline 7.10 & 0.50 & 222 \\ 7.5 & 0.75 & 1.75 \\ 11.00 & 5.40 & 411 \\ \hline 7.10 & 0.50 & 220 \\ 1.00 & 1.00 & 121 \\ 1.20 & 5.30 & 110 \\ 1.20 & 5.30 & 110 \\ 1.20 & 5.30 & 121 \\ 1.20 & 5.30 & 110 \\ 1.20 & 1.25 & 99 \\ 6.00 & 1.30 & 159 \\ 1.30 & 1.30 & 311 \\ 1.30 & 3.60 & 331 \\ 1.30$ | 5.6% -2.8% 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -3. 3.4% 0. 3.4% 0. 3.4% 0. 3.4% 0. 3.4% -2. 3.4% -3. 3.2% -4. 3.3% -7. 2.0% -6. 2.9% -6. 2.9% -6. 2.9% -6. 3.3% -4. 3.4% -2. 3.1% -3. 3.3% -4. 3.4% -4. | [-0.83; 0.62] -4 dean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 75 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 10 [-10.62; -1.38] 10 [-10.63; -6.01] 10 [-3.82; -1.98] 10 [-3.43; -4.07] 10 [-3.43; -4.07] 10 [-3.41; -4.65] 31 [-6.19; -1.61] 10 [-3.81; -4.65] 31 [-6.19; -1.61] 10 [-1.80; -0.22] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; / Study Lo, C.M1996 Lai; P.B1998 Lo, C.M1996 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serrata, A.S2003 Kolle SE2004 Akyürek, N2005 Stevens, K. A2006 Al-Mulhim2006 Macafee DA2009 Yadav RP2009 González-Rodriguez, FJ2009 Chang, T C2009 Chang, T C20012 Chang, T C20012 Chang, T C2012 Chang, T C2012 | $\begin{array}{cccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 & 2.23 & 1503 \\ \end{array} \\ \begin{array}{c} 2365 & 2365 \\ \hline \\ $ | $\begin{array}{cccc} 5.74 & 2.43 & 1644 \\ & & & & & & & & \\ \hline & & & & & & & \\ \hline & & & &$ | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -1. 3.4% -3. 3.4% -3. 3.4% -3. 3.2% -4. 3.1% -1. 3.4% -2. 3.4% -3. 3.2% -9. 3.5% -7. 3.4% -2. 3.1% -4. 3.4% -0. 3.5% -3. 3.3% -4. 3.4% 0. 3.5% -3. 3.4% -4. 3.4% 0. 3.5% -3. 3.4% -4. 3.4% -1. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. .4. 3.4% | [-0.83; 0.62] -4 dean Difference: Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.43] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-3.63; -1.98] 90 [-1.447; -11.33] 30 [-5.57; -3.43] 60 [-5.13; -4.07] 00 [-0.83] 00 [-3.41; -2.59] 33 [-6.01; -4.65] 33 [-6.01; -4.65] 33 [-6.01; -4.65] 34 [-5.19; -1.61] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; · Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kotla SB2004 Akyūrek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafeo DA2009 GonzálezRodríguez, FJ2009 Chang, T C2009 GonzálezRodríguez, FJ2009 Chang, T C2009 Chang, T C2009 | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $\begin{array}{c cccc} 5.74 & 2.43 & 1644 \\ & & & & & & & & & & & & \\ \hline & & & & &$ | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -4. 3.1% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -3. 3.2% -4. 3.4% -2. 3.4% -3. 3.5% -1. 3.3% -4. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -4. 3.4% -4. 3.4% -4. 3.4% -4. 3.4% -3. 3.5% -3. 3.4% -4. 3.4% -4. 3.4% -4. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. | [-0.83; 0.62] -4 dean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-3.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.25; -0.75] 10 [-8.19; -6.01] 00 [-0.65] 90 [-3.82; -1.38] 90 [-1.447; -11.33] 90 [-3.82; -1.38] 90 [-3.82; -1.59] 90 [-3.82; -0.59] 90 [-2.1; -0.59] 33 [-6.01; -4.65] 30 [-3.37; -1.63] 44 [-5.37; -3.51] 90 [-3.57; -2.43] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; ; Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Chandler CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A S2003 Kolla SB2004 Akyürek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafee DA2009 González-Rodríguez, FJ2009 Choi, S B2011 Zhu, Bin2012 Panagiotopulou2012 Faior, A:E2012 Han, I.W2012 Gui R2013 Guitz2013 Gwor, RM2015 | $\begin{array}{c ccccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \hline \\ 2.86 & 2.22 & 1503 \\ \hline \\ 2.86 & 2.22 & 1503 \\ \hline \\ \hline \\ \\ \hline \\ \hline \\ \\ \hline \\ \hline \\ \hline \\ \\ \hline \hline \\ \hline \\ \hline \\ \hline \\ \hline \hline \\ \hline \\ \hline \hline \\ \hline \\ \hline \hline \\ \hline \hline \\ \hline \\ \hline \hline \\ \hline \hline \\ \hline \hline \\ \hline \\ \hline \hline \hline \\ \hline \hline \\ \hline \hline \\ \hline \hline \hline \\ \hline \hline \hline \\ \hline \hline \hline \\ \hline \hline \hline \hline \\ \hline \hline \hline \hline \hline \\ \hline \hline$ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | 5.6% -2.8% 100.0% -0.11 Weight IV 100.0% -0.11 3.0% -0.11 3.1% -1. 3.4% -2. 3.4% -3. 3.2% -4. 3.4% -2. 3.4% -2. 3.4% -3. 3.2% -1. 3.3% -1. 3.4% 0. 3.4% 0. 3.4% -2. 3.1% -3. 3.3% -1. 3.3% -1. 3.3% -1. 3.4% -2. 3.3% -3. 3.4% -3. 3.4% -4. 3.4% -3. 3.4% -4. 3.4% -4. 3.4% -4. 3.4% -4. 3.4% -4. 3.4% -4. 3.4% -4. <td>[-0.83; 0.62] -4 dean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.25; -0.75] 10 [-10.62; -1.38] 90 [-1.23; -7.49] 90 [-1.23; -7.49] 90 [-1.23; -0.75] 10 [-8.19; -6.01] 90 [-3.82; -1.98] 90 [-3.82; -1.98] 90 [-3.82; -1.98] 90 [-3.41; -2.59] 90 [-3.41; -2.59] 90 [-3.41; -2.59] 90 [-3.41; -4.51] 33 [-6.01; -4.65] 33 [-6.01; -4.65] 33 [-6.0]; -4.65] 33 [-6.01; -4.65] 33 [-6.0]; -4.65] 34 [-5.37]; -1.83] 44 [-5.37]; -1.83] 44 [-5.37]; -3.51]</td> <td>Mean Difference IV, Random, 95% CI</td> | [-0.83; 0.62] -4 dean Difference Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.25; -0.75] 10 [-10.62; -1.38] 90 [-1.23; -7.49] 90 [-1.23; -7.49] 90 [-1.23; -0.75] 10 [-8.19; -6.01] 90 [-3.82; -1.98] 90 [-3.82; -1.98] 90 [-3.82; -1.98] 90 [-3.41; -2.59] 90 [-3.41; -2.59] 90 [-3.41; -2.59] 90 [-3.41; -4.51] 33 [-6.01; -4.65] 33 [-6.01; -4.65] 33 [-6.0]; -4.65] 33 [-6.01; -4.65] 33 [-6.0]; -4.65] 34 [-5.37]; -1.83] 44 [-5.37]; -1.83] 44 [-5.37]; -3.51] | Mean Difference IV, Random, 95% CI |
| Khalid2017 Wu, Hongsheng2021 Total (95% CI) Heterogeneity: Tau ² = 2.4357 ; ; Study Lo, C.M1996 Lai, P.B1998 Lo, C.M1996 Lai, P.B1998 Lo, C.M1998 Lo, C.M1998 Lo, C.M1998 Lo, C.M1998 Schaller CF2000 Bhattacharya2002 Madan, A K2002 Johansson, M2003 Serralta, A.S2003 Kolta SE2004 Akyűrek, N2005 Stevens, K. A2006 Al-Mulhim2008 Macafee DA2009 González–Rodriguez, FJ2009 Chois, S B2011 Zhu, Bin2012 Panagiotopoulou2012 Falor, A.E2012 Han, I.W2012 Guit R2013 Guit 2013 Guit 2013 Gorkardes AB2014 Agrawal R2015 Rodjin D2016 | $\begin{array}{c ccccc} 1.67 & 0.89 & 90 \\ 2.86 & 2.22 & 1503 \\ \hline \\ 2.86 & 2.22 & 1503 \\ \hline \\ 1500 & 2365 & 2365 \\ \hline \\ $ | $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | 5.6% -2.88 100.0% -0.11 Weight IV 2.0% -8. 3.2% -4. 3.1% -4. 3.1% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.4% -2. 3.5% -1. 3.3% -4. 3.4% -2. 3.1% -3. 3.3% -4. 3.4% -2. 3.1% -3. 3.3% -4. 3.4% -3. 3.5% -3. 3.4% -3. 3.5% -3. 3.5% -3. 3.5% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. 3.4% -3. | [-0.83; 0.62] -4 dean Difference: Random, 95% CI 40 [-13.02; -3.78] 00 [-5.45; -2.55] 00 [-6.90; -3.10] 70 [-2.03; -1.37] 25 [-0.60; 1.10] 30 [-2.97; -1.63] 00 [-3.68; -2.32] 80 [-9.37; -6.23] 00 [-1.25; -0.75] 10 [-1.38] -00 [-1.25; -0.75] 10 [-1.38] -00 [-1.38] -00 [-1.38] -00 [-3.82; -1.38] 30 [-5.57; -3.43] 30 [-5.50; -3.43] 30 [-5.50; -3.43] 30 [-5.13; -4.07] 00 [-3.81; -4.65] 31 [-6.01] -0.83] 00 [-3.41; -2.59] 33 [-6.01; -4.65] 33 [-6.01; -4.65] 34 [-5.13; -1.81] 44 [-5.37; -3.51] 00 [-3.57; -2.43] 10 [-5.60] -2.60] | Mean Difference IV, Random, 95% CI |

Forest plots of secondary outcomes between ELC and DLC. (A) Operation time; (B) Postoperative hospital stay duration; (C) Total hospital stay duration. Green squares represent the point estimates of the treatment effect OR, with 95% CI indicated by horizontal bars. Blue diamonds represent the summary estimate from the pooled studies with 95% CI using random effected models.

| Study or | ELC | | | DLC | | | | Mean Difference | Mean Difference | |
|--|-------------------------|-----------|--------------|--------------------|---------------|----------|--------|-------------------------|---------------------------------------|--|
| Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | |
| ubLocation = America | | | | | | | | | | |
| Garber, S. M1997 | 100.00 | 37.00 | 109 | 120.00 | 55.00 | 85 | 3.5% | -20.00 [-33.60; -6.40] | — <u>—</u> | |
| Chandler CF2000 | 115.00 | 8.00 | 21 | 125.00 | 11.00 | 22 | 4.2% | -10.00 [-15.73; -4.27] | | |
| Madan, A K2002 | 73.00 | 21.00 | 14 | 92.00 | 36.00 | 31 | | -19.00 [-35.78; -2.22] | _ | |
| Stevens, K. A2006 | 105.00 | | 82 | 126.00 | | 114 | | -21.00 [-35.96; -6.04] | _ | |
| Total (95% CI) | | | 226 | | | 252 | | -15.08 [-22.09; -8.08] | - | |
| Heterogeneity: $Tau^2 = 17.2934$; | $Chi^2 = 3.60$ | 6, df = 3 | | 30); $I^2 = 18$ | 3% | | / • | ····· | | |
| subLocation = Asia | | | | | | | | | | |
| Lai, P.B1998 | 122.80 | 36.00 | 53 | 106.60 | 37.30 | 38 | 3.3% | 16.20 [0.88; 31.52] | | |
| Lo, C.M1998 | 135.00 | | 45 | 105.00 | | 41 | 2.3% | 30.00 [3.21; 56.79] | | |
| Kolla SB2004 | 104.00 | | 20 | 93.00 | | 20 | 3.8% | 11.00 [0.73; 21.27] | — | |
| Stevens, K. A2006 | | 41.00 | 132 | 95.00 | | 121 | 3.8% | -3.00 [-12.99; 6.99] | | |
| Yadav RP2009 | | 35.79 | 21 | 61.67 | | 22 | 3.1% | 33.09 [15.89; 50.29] | | |
| Chang, T C2009 | 109.00 | | 56 | 77.00 | | 33 | 3.5% | 32.00 [18.67; 45.33] | | |
| Choi, S B2011 | | 23.20 | 57 | 107.00 | | 59 | 3.8% | -9.00 [-19.90; 1.90] | | |
| Zhu, Bin2012 | 44.10 | 5.31 | 34 | 66.40 | 3.05 | 99 | | -22.30 [-24.18; -20.42] | | |
| Han, I. W2012 | | 25.30 | 21 | 53.70 | | 46 | 3.2% | 25.60 [8.62; 42.58] | · · · · · · · · · · · · · · · · · · · | |
| Gul R2013 | | 12.40 | 30 | 80.67 | | 30 | 4.1% | 18.16 [11.33; 24.99] | | |
| Kwon, Y.J2013 | | 29.30 | 33 | 71.40 | | 28 | 3.6% | 4.10 [-8.32; 16.52] | | |
| Agrawal R2015 | | 29.50 | 25 | 66.40 | | 28 | 3.5% | 3.00[-10.18; 16.18] | | |
| Khalid2017 | | 12.30 | 23 90 | 58.24 | | 23 90 | 4.3% | 6.08 [2.31; 9.85] | | |
| Davoodabadi2020 | 83.70 | 7.49 | 104 | 81.73 | | 104 | 4.3% | 1.97 [-0.50; 4.44] | | |
| | | 25.67 | | | 26.94 | | 4.3% | 0.33[-1.51; 2.17] | | |
| Wu, Hongsheng2021 | 82.48 | 25.67 | 1505 2224 | 82.15 | 26.94 | | | . , , | | |
| Fotal (95% CI) Heterogeneity: Tau ² = 211.7478 | C1 ·2 | 0 71 10 | | -0.01) - | 2 070 | 2400 | 55.3% | 8.29 [0.32; 16.25] | | |
| | ; Cni = 55 | 2.71, di | = 14 (P | < 0.01); 1 | = 97% |) | | | | |
| subLocation = Europe Bhattacharya2002 | 78.00 | 15.75 | 33 | 91.75 | 18.75 | 17 | 3.8% | -13.75 [-24.16; -3.34] | <mark></mark> | |
| Serralta, A.S2003 | | 27.90 | 82 | 93.40 | | 87 | | -18.70 [-29.38; -8.02] | | |
| Johansson, M2003 | | 30.00 | 74 | 100.00 | | 69 | 3.6% | -2.00 [-14.63; 10.63] | | |
| González-Rodríguez, F.J2009 | | 31.00 | 102 | 85.50 | | 434 | 4.1% | -5.70 [-12.56; 1.16] | | |
| Ozkardes AB2014 | 67.00 | | 30 | 71.33 | | 30 | 3.5% | -4.33 [-17.68; 9.02] | | |
| Roulin D2016 | | 15.00 | 42 | 88.00 | | 44 | 4.1% | 3.00 [-3.77; 9.77] | | |
| Rajcok, M2016 | | 23.30 | 31 | 90.00 | | 31 | | -14.10 [-28.18; -0.02] | | |
| sil, R.G2021 | | 23.50 | 88 | 50.50 | | 88 | 4.1% | 9.50 [2.24; 16.76] | | |
| Fotal (95% CI) | 00.00 | 20.00 | 482 | 50.50 | 20.00 | 800 | 30.4% | | | |
| Heterogeneity: $Tau^2 = 71.3369$; | $Chi^2 = 29.8$ | 85, df = | | $.01$); $I^2 = 7$ | 77% | 000 | 501170 | | - | |
| Fotal (95% CI) | | | 2932 | | | 3452 | 100.0% | 0.46 [-5.35; 6.27] | | |
| Heterogeneity: $Tau^2 = 202.6737$ | ; Chi ² = 59 | 8.84, df | = 26 (P | < 0.01); I | $^{2} = 96\%$ | | | • • • | | |
| Test for subgroup differences: C | | | | | | | | | -40 -20 0 20 | |

Subgroup analysis of location factors for operation time between ELC and DLC. (A) Subgroup for American population; (B) Subgroup for Asian population; (C) Subgroup for European population.

3.7 Meta-regression for investigating sources of heterogeneity

Furthermore, we analyzed the heterogeneity source using a Metaregression analysis, revealing that the operation time and location accounted for the heterogeneity among studies (z=2.5294, 95%CI: 4.9790–39.2566, p=0.0114), consistent with the results of subgroup analysis (Figure 7).

4 Discussion

Since the first laparoscopic cholecystectomy was successfully performed in the late 1980s, minimally invasive surgery has been increasingly used to treat biliary tract diseases. Nowadays, LC has become the most common surgical approach for cholecystectomy. Due to the limitations of this new technology in the early days, laparoscopic cholecystectomy was not recommended for patients who suffered from acute cholecystitis due to the severe edema, the unclear anatomic structure of the Calot triangle, the uncontrollable bleeding around the gallbladder and the degree of surgeon's experience (53-55). However, with the rapid development of laparoscopic technology and the refined understanding of intraoperative and postoperative complications of laparoscopic cholecystectomy, performing laparoscopic cholecystectomy for acute cholecystitis in the early period is no longer regarded as a contraindication (56, 57). Nevertheless, little is currently known about the optimal timing. Indeed, during the initial stages of acute cholecystitis, acute inflammatory reaction and edematous connective tissues impede the dissection of Calot's triangle, contributing to reactive hyperemia and increase bleeding and bile duct injury during ELC. Accordingly, this may increase the operative time due to the severe inflammatory response in the early period of acute cholecystitis patients. Indeed, a longer operative time may increase the open surgery conversion rate and risk of biliary damage. On the other hand, patients that undergo

| Subgroup | Mean | | | | | | | | Mean Difference | | |
|---|-----------------------|------------|--------|----------------------------|---------------|-------|--------|-------------------------|--------------------|--|--|
| | wican | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | | |
| ubLocation = Asia | | | | | | | | | | | |
| .o, C.M1996 | 6.70 | 4.10 | 27 | 15.10 | 11.10 | 25 | 2.0% | -8.40 [-13.02; -3.78] | | | |
| .ai, P.B1998 | 7.60 | 3.60 | 53 | 11.60 | 3.40 | 38 | 3.2% | -4.00 [-5.45; -2.55] | <u>₩</u> | | |
| .o, C.M1998 | 6.00 | 3.20 | 45 | 11.00 | 5.40 | 41 | 3.1% | -5.00 [-6.90; -3.10] | - | | |
| Kolla SB2004 | 4.10 | 8.60 | 20 | 10.10 | 6.10 | 20 | 2.0% | -6.00 [-10.62; -1.38] | | | |
| Al-Mulhim2008 | 5.10 | 2.30 | 82 | 12.20 | 5.30 | 114 | 3.3% | -7.10 [-8.19; -6.01] | ₩ | | |
| radav RP2009 | 4.33 | 1.46 | 21 | 7.23 | 1.63 | 22 | 3.4% | -2.90 [-3.82; -1.98] | ••• | | |
| Chang, T C2009 | 4.50 | 4.40 | 56 | 7.80 | 4.80 | 33 | 3.1% | -3.30 [-5.30; -1.30] | | | |
| Choi, S B2011 | 6.80 | 2.10 | 57 | 11.30 | 3.60 | 59 | 3.3% | -4.50 [-5.57; -3.43] | | | |
| Zhu, Bin2012 | 7.50 | 1.41 | 34 | 12.10 | 1.25 | 99 | 3.4% | -4.60 [-5.13; -4.07] | • | | |
| Ian, I.W2012 | 10.80 | 4.50 | 21 | 14.70 | 9.30 | 46 | 2.5% | -3.90 [-7.21; -0.59] | — <u>—</u> | | |
| Gul R2013 | 4.77 | 1.30 | 30 | 10.10 | 1.40 | 30 | 3.4% | -5.33 [-6.01; -4.65] | ••• | | |
| Kwon, Y.J2013 | 5.30 | 2.40 | 33 | 8.70 | 4.30 | 28 | 3.1% | -3.40 [-5.19; -1.61] | | | |
| Jomes,RM2013 | 3.02 | 0.87 | 21 | 4.03 | 2.24 | 40 | 3.4% | -1.01 [-1.80; -0.22] | | | |
| Agrawal R2015 | 4.16 | 1.21 | 25 | 8.60 | 2.04 | 25 | 3.4% | -4.44 [-5.37; -3.51] | 1 | | |
| Davoodabadi2020 | 3.66 | 1.12 | 104 | 10.35 | 1.76 | 104 | 3.5% | -6.69 [-7.09; -6.29] | • | | |
| fotal (95% CI) | | | 629 | | | 724 | 46.3% | -4.52 [-5.43; -3.61] | • | | |
| <pre>leterogeneity: Tau² = 2.5202 ; C ubLocation = America</pre> | | , . , , (1 | 14 (| | 1 747 | /0 | | | | | |
| Chandler CF2000 | 5.40 | 0.60 | 21 | 7.10 | 0.50 | 22 | 3.5% | -1.70 [-2.03; -1.37] | - | | |
| Jadan,A K2002 | 2.10 | 0.70 | 14 | 4.40 | 1.60 | 31 | 3.4% | -2.30 [-2.97; -1.63] | | | |
| tevens, K. A2006 | 2.00 | 1.00 | 132 | 3.00 | 1.00 | 121 | 3.5% | -1.00 [-1.25; -0.75] | • | | |
| alor, A.E2012 | 3.00 | 1.20 | 117 | 6.00 | 2.40 | 186 | 3.5% | -3.00 [-3.41; -2.59] | | | |
| otal (95% CI) | | | 284 | | | 360 | 13.8% | -1.98 [-2.84; -1.13] | • | | |
| leterogeneity: Tau ² = 0.7105 ; C | $2hi^2 = 72.4$ | 2, df= | 3 (P < | < 0.01); \mathbb{I}^2 | = 96% | | | | | | |
| ubLocation = Europe | | | | | | | | | | | |
| 3hattacharya2002 | | 2.25 | 33 | 7.75 | 0.75 | 17 | 3.4% | 0.25 [-0.60; 1.10] | | | |
| ohansson, M2003 | | 1.50 | 74 | 8.00 | 2.50 | 69 | 3.4% | -3.00 [-3.68; -2.32] | | | |
| Serralta, A.S2003 | | 4.60 | 82 | 13.40 | 5.80 | 87 | 3.2% | -7.80 [-9.37; -6.23] | | | |
| Akyürek, N2005 | | 2.70 | 31 | 15.20 | 6.20 | 30 | 2.9% | -9.90 [-12.31; -7.49] | - | | |
| Macafee DA2009 | | 1.30 | 36 | 6.00 | 1.50 | 36 | 3.4% | 0.00 [-0.65; 0.65] | | | |
| González–Rodríguez, F.J2009 | | 6.10 | 102 | | 11.00 | 434 | | -12.90 [-14.47; -11.33] | ₩ <u> </u> | | |
| anagiotopoulou2012 | | 1.20 | 21 | 6.00 | 1.30 | 15 | 3.4% | 0.00 [-0.83; 0.83] | = | | |
| Gutt2013 | | 1.20 | 304 | 10.03 | 1.10 | 314 | 3.5% | -4.63 [-4.81; -4.45] | | | |
| Ozkardes AB2014 | | 1.40 | 30 | 7.80 | 1.65 | 30 | 3.4% | -2.60 [-3.37; -1.83] | | | |
| Roulin D2016 | | 1.20 | 42 | 7.00 | 1.50 | 44 | 3.4% | -3.00 [-3.57; -2.43] | | | |
| Rajcok, M2016 | | 2.10 | 31 | 11.50 | 3.70 | 31 | 3.2% | -4.10 [-5.60; -2.60] | # | | |
| sil, R.G2021 | 1.50 | 0.90 | 88 | 5.50 | 4.30 | 88 | 3.4% | -4.00 [-4.92; -3.08] | | | |
| Fotal (95% CI) | | | 874 | | | 1195 | 39.9% | -4.24 [-6.50; -1.97] | ~ | | |
| Ieterogeneity: Tau ² = 15.6628 ; | $\mathrm{Chi}^2 = 57$ | 7.49, d | f=11 | (P < 0.01 |); $I^2 = 98$ | 3% | | | | | |
| fotal (95% CI) | | | 1787 | | | 2279 | 100.0% | -4.07 [-5.07; -3.06] | | | |
| Heterogeneity: $Tau^2 = 7.6196$; C | $2hi^2 = 150$ | 9.94, d | f = 30 | (P < 0.01 |); $I^2 = 98$ | 3% | | | | | |
| | $chi^2 = 16.6$ | | | | | | | | -10 -5 0 5 | | |

Subgroup analysis of location factors for total hospital stay duration between ELC and DLC. (A) Subgroup for Asian population; (B) Subgroup for American population; (C) Subgroup for European population.

DLC may benefit from a decreased conversion rate and risk of complications while prolonging hospitalization and increasing medical expenses (24, 58, 59).

Although several meta-analysis studies have compared ELC and DLC, they have some limitations. In this respect, Siddiqui et al. (60) and Gurusamy et al. (61) conducted studies based on a limited number of research and patients, suggesting significant bias in their studies. Complications of LC consist of intraoperative and postoperative complications. The most common intraoperative complications are bile duct injury, intraoperative bleeding, and conversion to open surgery. Bile duct injury is more serious and can be treated via *T*-tube placement. In cases of delayed diagnosis, ERCP may be performed after LC, but biliary stricture and recurrent

biliary tract infection may occur. The most common postoperative complications are bile leak, wound site infection, and fluid collection around the gallbladder fossa. Bile leak may be the most serious among these, leading to acute peritonitis and septic shock. Current strategies to solve bile leakage include (1). Evaluation of the anatomical structure of the biliary tract; (2). For relatively small leaks, an indwelling abdominal tube should be placed for adequate drainage; (3). For relatively large leaks, a biliary stent may be inserted by ERCP (62, 63). Indeed, during the early stages of acute cholecystitis, gallbladder congestion, edema, brittle tissue bleeding and other factors may make laparoscopic dissection more challenging and constitute the main reason for conversion to laparotomy.

| Jutcomes | Subgroup | Estimate | p value | Lower 95%CI | Upper 95%CI | ELC group DLC group |
|-------------------------|--------------|----------|---------|----------------|----------------|---------------------------------------|
| Operation Time | | | | | | _ |
| | Study Design | -8.4701 | 0.219 | -21.9767 | 5.0364 | |
| | Location | 22.1178 | 0.0114 | 4.979 | 39.2566 | · |
| | Year | 1.7732 | 0.7838 | -10.8912 | 14.4376 | ⊢ |
| | Timing of LC | -2.869 | 0.6952 | -17.2192 | 11.4811 | |
| otal Hospital Stay Time | | | | | | |
| | Study Design | 0.6087 | 0.6201 | -1.798 | 3.0154 | · · · · · · · · · · · · · · · · · · · |
| | Location | -2.4065 | 0.1729 | -5.8675 | 1.0544 | H B |
| | Year | -1.1315 | 0.3658 | -3.5835 | 1.3205 | - |
| | Timing of LC | 0.9115 | 0.4551 | -1.4802 | 3.3033 | ÷ |

Meta regression of operation time and total hospital stay time between ELC and DLC. The results indicated that location factor was responsible for the source of heterogeneity with statistical significance (OR = 22.1178, 95%CI: 4.979–39.2566).

Our meta-analysis found that compared with ELC, DLC was associated with a high conversion rate and high postoperative complications with a fixed-effects model. However, the total hospitalization time in ELC was significantly shorter than in DLC when a random-effects model was utilized. In order to assess the heterogeneity in this meta-analysis, subgroup analysis and metaregression were also employed, and both approaches indicated that regional factors accounted for the heterogeneity of this study. Subgroup analysis according to the operation time indicated that compared with Europe and America, a significantly longer operation time was observed for ELC patients in Asia, which suggested that acute inflammation and other factors during the early stage of acute cholecystitis were inclined to prolong the operation time in Asia (35, 36). During the subgroup analysis of hospitalization duration, we found that patients that underwent DLC in America correlated with shorter hospitalization than in Asia or Europe. The longest hospitalization duration was 7.10 ± 0.50 days (14) in America, which was shorter than in Asia $(15.1 \pm 11.1 \text{ days})$ (34) and Europe $(20.5 \pm 11.0 \text{ days})$ (26). This finding may account for the heterogeneity in our meta-analysis.

To investigate the stability and reliability of our findings, a sensitivity analysis was performed by removing one study each time. No study interfered with the results of this meta-analysis, substantiating the stability and reliability of our pooled estimates (Appendix 7). To analyze the possible presence of publication bias in this meta-analysis, we conducted an Egger's test and generated funnel plots. Egger's test showed that the funnel plots of intraoperative complications and postoperative hospital stay time were asymmetric. Next, we evaluated the impact of publication bias on the results by using the trim-and-fill method. It was found that with 4 added studies on intraoperative complications, there was no significant change in OR, WMD and their corresponding p values. Our funnel plot with filled-in data which

was based on the trim-and-fill approach exhibited a symmetrical distribution (Figure 8).


Several limitations found in this meta-analysis should be acknowledged. First, about one-third of the studies were retrospective studies, and the blinding method was not mentioned, which impacted the quality of included studies. Besides, studies from different locations accounted for the heterogeneity in this metaanalysis. Selecting uniform RCTs might reduce the heterogeneity, but it would increase the risk of bias. Moreover, for publication bias on intraoperative complications and postoperative hospital stay time, although the funnel plot with filled-in data based on the trim-and-fill approach exhibited a symmetrical distribution, other factors such as study design, exceeding positive results and greater weight mean difference may account for publication bias. Accordingly, more largescale, high-quality RCTs are required in the future.

5 Conclusion

This meta-analysis revealed that compared with DLC, ELC was associated with a lower conversion rate and incidence of postoperative complications and shorter hospitalization duration for acute cholecystitis. ELC brings significant advantages in terms of safety profile and cost-effectiveness. Nevertheless, despite our rigorous methodology, some limitations were still unavoidable. Large-scale and high-quality RCTs with long follow-ups are warranted to validate the findings of this meta-analysis.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.



rate; **B**: Intraoperative complications; **C**:Postoperative complications), the *x*-axis stood for odds ratio, while y-axis stood for standard error. (**D**–**F**) represented the funnel plots of secondary outcomes (**D**: Operation time; **E**: Postoperative hospital stay time; **F**: Total hospital stay time), the *x*-axis stood for mean difference while y-axis stood for standard error. Both funnel plots of **B**,**D**,**E** using trim-and-fill method, after filling studies indicated as hollow circle dots in the funnel plots, the funnel plot is basically symmetrical.

Author contributions

HW and KM: study concept and design. TJ and JH: acquisition of data. HW and BL: statistical analysis and manuscript writing. TC and YL: generation of statistical figures. HW, BL, TC, TJ, JH, YL, and KM: final approval of manuscript. All authors contributed to the article and approved the submitted version.

Funding

This research was supported by the Internal Medicine Research Fund (Grant no 2020A01) and the Construction of Major Subject [Grant no (YNZDXK202201, 2022-2025)] of Affiliated Huadu Hospital, Southern Medical University.

Acknowledgments

We would like to thank the Internal Medicine Research Fund of Affiliated Huadu Hospital, Southern Medical University for their support.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2023.1185482/ full#supplementary-material

References

1. Campanile FC, Pisano M, Coccolini F, Catena F, Agresta F, Ansaloni L. Acute cholecystitis: WSES position statement. *World J Emerg Surg.* (2014) 9:58. doi: 10.1186/1749-7922-9-58

2. Popkharitov AI. Laparoscopic cholecystectomy for acute cholecystitis. Langenbeck's Arch Surg. (2008) 393:935–41. doi: 10.1007/s00423-008-0313-7

3. Wakabayashi G, Iwashita Y, Hibi T, Takada T, Strasberg SM, Asbun HJ, et al. Tokyo guidelines 2018: surgical management of acute cholecystitis: safe steps in laparoscopic cholecystectomy for acute cholecystitis (with videos). *J Hepatobiliary Pancreat Sci.* (2018) 25:73–86. doi: 10.1002/jhbp.517

4. Garber SM, Korman J, Cosgrove JM, Cohen JR. Early laparoscopic cholecystectomy for acute cholecystitis. *Surg Endosc.* (1997) 11:347–50. doi: 10.1007/s004649900360

5. Lee W, Kwon J. Delayed laparoscopic cholecystectomy after more than 6 weeks on easily controlled cholecystitis patients. Korean. *J Hepato-Biliary-Pancreat Surg.* (2013) 17:60–5. doi: 10.14701/kjhbps.2013.17.2.60

6. Graves HA, Ballinger JF, Anderson WJ. Appraisal of laparoscopic cholecystectomy. *Ann Surg.* (1991) 213:655–64. doi: 10.1097/0000658-199106000-00017

7. Wilson RG, Macintyre IM, Nixon SJ, Saunders JH, Varma JS, King PM. Laparoscopic cholecystectomy as a safe and effective treatment for severe acute cholecystitis. *BMJ*. (1992) 305:394–6. doi: 10.1136/bmj.305.6850.394

8. Kum CK, Goh PM, Isaac JR, Tekant Y, Ngoi SS. Laparoscopic cholecystectomy for acute cholecystitis. *Br J Surg.* (1994) 81:1651–4. doi: 10.1002/bjs.1800811130

9. Aziret M, Karaman K, Ercan M, Vargol E, Toka B, Arslan Y, et al. Early laparoscopic cholecystectomy is associated with less risk of complications after the removal of common bile duct stones by endoscopic retrograde cholangiopancreatography. *Turk J Gastroenterol.* (2019) 30:336–44. doi: 10.5152/tjg.2018.18272

10. Lo HC, Wang YC, Su LT, Hsieh CH. Can early laparoscopic cholecystectomy be the optimal management of cholecystitis with gallbladder perforation? A single institute experience of 74 cases. *Surg Endosc.* (2012) 26:3301–6. doi: 10.1007/s00464-012-2344-y

11. Strobel O, Büchler MW. Early laparoscopic cholecystectomy as therapy of choice for acute cholecystitis. *Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.* (2013) 84:999. doi: 10.1007/s00104-013-2633-6

12. Khalid S, Iqbal Z, Bhatti AA. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis. J Ayub Med Coll Abbottabad. (2017) 29:570–3.

13. Panagiotopoulou IG, Carter N, Lewis MC, Rao S. Early laparoscopic cholecystectomy in a district general hospital: is it safe and feasible? *Int J Evid Based Healthc*. (2012) 10:112–6. doi: 10.1111/j.1744-1609.2012.00260.x

14. Chandler CF, Lane JS, Ferguson P, Thompson JE, Ashley SW. Prospective evaluation of early versus delayed laparoscopic cholecystectomy for treatment of acute cholecystitis. *Am Surg.* (2000) 66:896–900. doi: 10.1177/000313480006600921

15. Han IW, Jang JY, Kang MJ, Lee KB, Lee SE, Kim SW. Early versus delayed laparoscopic cholecystectomy after percutaneous transhepatic gallbladder drainage. *J Hepatobiliary Pancreat Sci.* (2012) 19:187–93. doi: 10.1007/s00534-011-0458-6

16. Skouras C, Jarral O, Deshpande R, Zografos G, Habib N, Zacharakis E. Is early laparoscopic cholecystectomy for acute cholecystitis preferable to delayed surgery?: best evidence topic (BET). *International journal of surgery (London, England)*. (2012) 10:250–8. doi: 10.1016/j.ijsu.2012.04.012

17. Pisano M, Ceresoli M, Allegri A, Belotti E, Coccolini F, Colombi R, et al. Single center retrospective analysis of early vs. delayed treatment in acute calculous cholecystitis: application of a clinical pathway and an economic analysis. *Ulusal travma ve acil cerahi dergisi = Turkish journal of trauma & emergency surgery: TJTES.* (2015) 21:373–9. doi: 10.5505/tjtes.2015.62679

18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis of observational studies in epidemiology (MOOSE) group. *JAMA*. (2000) 283:2008–12. doi: 10.1001/jama.283.15.2008

19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. (2021) 372:n71. doi: 10.1136/bmj.n71

20. Fletcher E, Seabold E, Herzing K, Markert R, Gans A, Ekeh AP. Laparoscopic cholecystectomy in the acute care surgery model: risk factors for complications. *Trauma Surg Acute Care Open*. (2019) 4:e000312. doi: 10.1136/tsaco-2019-000312

21. Konstadoulakis MM, Antonakis PT, Karatzikos G, Alexakis N, Leandros E. Intraoperative findings and postoperative complications in laparoscopic cholecystectomy_ the Greek experience with 5,539 patients in a single center. *J Laparoendosc Adv Surg Tech A*. (2004) 14:31–6. doi: 10.1089/109264204322862333

22. DeMets DL. Methods for combining randomized clinical trials_ strengths and limitations. *Stats in Medicine*. (1987) 6:341–8. doi: 10.1002/sim.4780060325

23. Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers' to authors' assessments. *BMC Med Res Methodol.* (2014) 14:45. doi: 10.1186/1471-2288-14-45

24. Madan AK, Aliabadi-Wahle S, Tesi D, Flint LM, Steinberg SM. How early is early laparoscopic treatment of acute cholecystitis. *Am J Surg*. (2002) 183:232–6. doi: 10.1016/S0002-9610(02)00789-4

25. Stevens KA, Chi A, Lucas LC, Porter JM, Williams MD. Immediate laparoscopic cholecystectomy for acute cholecystitis: no need to wait. *Am J Surg.* (2006) 192:756–61. doi: 10.1016/j.amjsurg.2006.08.040

26. González-Rodríguez FJ, Paredes-Cotoré JP, Pontón C, Rojo Y, Flores E, Luis-Calo ES, et al. Early or delayed laparoscopic cholecystectomy in acute cholecystitis conclusions of a controlled trial. *Hepato-Gastroenterology*. (2009) 56:11–6.

27. Chang T-C, Lin M-T, Wu M-H, Wang M-Y, Lee P-H. Evaluation of early versus delayed laparoscopic cholecystectomy in the treatment of acute cholecystitis. *Hepato-Gastroenterology*. (2009) 56:26–8.

28. Choi SB, Han HJ, Kim CY, Kim WB, Song T-J, Suh SO, et al. Early laparoscopic cholecystectomy is the appropriate management for acute gangrenous cholecystitis. Am Surg. (2011) 77:401–6. doi: 10.1177/000313481107700412

29. Falor AE, de Virgilio C, Stabile BE, Kaji AH, Caton A, Kokubun BA, et al. Early laparoscopic cholecystectomy for mild gallstone pancreatitis: time for a paradigm shift. *Arch Surg.* (2012) 147:1031–5. doi: 10.1001/archsurg.2012.1473

30. Zhu B, Zhang Z, Wang Y, Gong K, Lu Y, Zhang N. Comparison of laparoscopic cholecystectomy for acute cholecystitis within and beyond 72 h of symptom onset during emergency admissions. *World J Surg.* (2012) 36:2654–8. doi: 10.1007/s00268-012-1709-7

31. Kwon YJ, Ahn BK, Park HK, Lee KS, Lee KG. What is the optimal time for laparoscopic cholecystectomy in gallbladder empyema? *Surg Endosc.* (2013) 27:3776–80. doi: 10.1007/s00464-013-2968-6

32. Gomes RM, Mehta NT, Varik V, Doctor NH. No 72-hour pathological boundary for safe early laparoscopic cholecystectomy in acute cholecystitis: a clinicopathological study. *Ann Gastroenterol.* (2013) 26:340–5.

33. Wu H, Ma K, Yu L, Gu W, Yan Y, Wang B, et al. The timing of laparoscopic cholecystectomy and nano-ligation clip for acute calculous cholecystitis under guidance of Tokyo guidelines 2018 (multi-center retrospective analysis). *Mater Express.* (2021) 11:1681–90. doi: 10.1166/mex.2021.2085

34. Lo CM, Liu CL, Lai EC, Fan ST, Wong J. Early versus delayed laparoscopic cholecystectomy for treatment of acute cholecystitis. *Ann Surg.* (1996) 223:37–42. doi: 10.1097/00000658-199601000-00006

35. Lai PB, Kwong KH, Leung KL, Kwok SP, Chan AC, Chung SC, et al. Randomized trial of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. *Br J Surg*, (1998) 85:764–7. doi: 10.1046/j.1365-2168.1998.00708.x

36. Lo CM, Liu CL, Fan ST, Lai EC, Wong J. Prospective randomized study of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. *Ann Surg.* (1998) 227:461–7. doi: 10.1097/0000658-199804000-00001

37. Bhattacharya D, Senapati PSP, Hurle R, Ammori BJ. Urgent versus interval laparoscopic cholecystectomy for acute cholecystitis: a comparative study. *J Hepato-Biliary-Pancreat Surg.* (2002) 9:538–42. doi: 10.1007/s005340200070

38. Johansson M, Thune A, Blomqvist A, Nelvin L, Lundell L. Management of acute cholecystitis in the laparoscopic era_ results of a prospective, randomized clinical trial. *J gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract.* (2003) 7:642–5. doi: 10.1016/S1091-255X(03)00065-9

39. Serralta AS, Bueno JL, Planells MR, Rodero DR. Prospective evaluation of emergency versus delayed laparoscopic cholecystectomy for early cholecystitis. *Surg Laparosc Endosc Percutan Tech.* (2003) 13:71–5. doi: 10.1097/00129689-200304000-00002

40. Kolla SB, Aggarwal S, Kumar A, Kumar R, Chumber S, Parshad R, et al. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a prospective randomized trial. *Surg Endosc.* (2004) 18:1323–7. doi: 10.1007/s00464-003-9230-6

41. Akyürek N, Salman B, Yüksel O, Tezcaner T, Irkörücü O, Yücel C, et al. Management of acute calculous cholecystitis in high-risk patients_ percutaneous cholecystotomy followed by early laparoscopic cholecystectomy. *Surg Laparosc Endosc Percutan Tech*. (2005) 15:315–20. doi: 10.1097/01.sle.0000191619.02145.c0

42. Al-Mulhim AA. Timing of early laparoscopic cholecystectomy for acute cholecystitis. JSLS: Journal of the Society of Laparoendoscopic Surgeons. (2008) 12:282–7.

43. Macafee DA, Humes DJ, Bouliotis G, Beckingham IJ, Whynes DK, Lobo DN. Prospective randomized trial using cost-utility analysis of early versus delayed laparoscopic cholecystectomy for acute gallbladder disease. *Br J Surg.* (2009) 96:1031–40. doi: 10.1002/bjs.6685

44. Yadav RP, Adhikary S, Agrawal CS, Bhattarai B, Gupta RK, Ghimire A. A comparative study of early vs. delayed laparoscopic cholecystectomy in acute cholecystitis. *Kathmandu University medical journal (KUMJ)*. (2009) 7:16–20.

45. Gul R, Dar RA, Sheikh RA, Salroo NA, Matoo AR, Wani SH. Comparison of early and delayed laparoscopic cholecystectomy for acute cholecystitis: experience from a single center. *N Am J Med Sci.* (2013) 5:414–8. doi: 10.4103/1947-2714.115783

46. Gutt CN, Encke J, Köninger J, Harnoss JC, Weigand K, Kipfmüller K, et al. Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). *Ann Surg.* (2013) 258:385–93. doi: 10.1097/SLA.0b013e3182a1599b

47. Ozkardeş AB, Tokaç M, Dumlu EG, Bozkurt B, Ciftçi AB, Yetişir F, et al. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a prospective, randomized study. *Int Surg.* (2014) 99:56–61. doi: 10.9738/INTSURG-D-13-00068.1

48. Agrawal R, Sood KC, Agarwal B. Evaluation of early versus delayed laparoscopic cholecystectomy in acute cholecystitis. *Surgery research and practice*. (2015) 2015:349801:1–7. doi: 10.1155/2015/349801

49. Rajcok M, Bak V, Danihel L, Kukucka M, Schnorrer M. Early versus delayed laparoscopic cholecystectomy in treatment of acute cholecystitis. *Bratislavske lekarske listy*. (2016) 117:328–31. doi: 10.4149/BLL_2016_065

50. Roulin D, Saadi A, Di Mare L, Demartines N, Halkic N. Early versus delayed cholecystectomy for acute cholecystitis, are the 72 hours still the rule?: a randomized trial. *Ann Surg.* (2016) 264:717–22. doi: 10.1097/SLA.00000000001886

51. Davoodabadi A, Beigmohammadi E, Gilasi H, Arj A, Taheri NH. Optimizing cholecystectomy time in moderate acute biliary pancreatitis: a randomized clinical trial study. *Heliyon.* (2020) 6:e03388. doi: 10.1016/j.heliyon.2020.e03388

52. Isil RG, Yazici P, Isil CT, Mihmanli M. Does surgical experience really matter on the treatment approach to acute cholecystitis. A randomised clinical trial. *Ann Ital Chir.* (2021) 92:38–5.

53. Strasberg SM, Sanabria JR, Clavien PA. Complications of laparoscopic cholecystectomy. *Can J Surg.* (1992) 35:275–80.

54. Smith EB. Complications of laparoscopic cholecystectomy. J Natl Med Assoc. (1992) 84:880–2.

55. Delaitre B, Testas P, Dubois F, Mouret P, Nouaille JM, Suc B, et al. Complications of cholecystectomy by laparoscopic approach. Apropos of 6512 cases. *Chirurgie*. (1992) 118

56. Kiviluoto T, Sirén J, Luukkonen P, Kivilaakso E. Randomised trial of laparoscopic versus open cholecystectomy for acute and gangrenous cholecystitis. *Lancet.* (1998) 351:321–5. doi: 10.1016/S0140-6736(97)08447-X

57. Eldar S, Sabo E, Nash E, Abrahamson J, Matter I. Laparoscopic cholecystectomy for the various types of gallbladder inflammation: a prospective trial. *Surg Laparosc Endosc*. (1998) 8:200–7. doi: 10.1097/00019509-199806000-00008

58. Cameron IC, Chadwick C, Phillips J, Johnson AG. Acute cholecystitis--room for improvement? Ann R Coll Surg Engl. (2002) 84:10-3.

59. Rattner DW, Ferguson C, Warshaw AL. Factors associated with successful laparoscopic cholecystectomy for acute cholecystitis. *Ann Surg.* (1993) 217:233–6. doi: 10.1097/00000658-199303000-00003

60. Siddiqui T, MacDonald A, Chong PS, Jenkins JT. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a meta-analysis of randomized clinical trials. *Am J Surg.* (2008) 195:40–7. doi: 10.1016/j.amjsurg.2007.03.004

61. Gurusamy K, Samraj K, Gluud C, Wilson E, Davidson BR. Meta-analysis of randomized controlled trials on the safety and effectiveness of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. *Br J Surg.* (2010) 97:141–50. doi: 10.1002/bjs.6870

62. Karvonen J, Gullichsen R, Laine S, Salminen P, Grönroos JM. Bile duct injuries during laparoscopic cholecystectomy: primary and long-term results from a single institution. *Surg Endosc.* (2007) 21:1069–73. doi: 10.1007/s00464-007-9316-7

63. Sultan AM, Elnakeeb AM, Elshobary MM, El-Geidi AA, Salah T, El-Hanafy EA, et al. Management of post-cholecystectomy biliary fistula according to type of cholecystectomy. *Endosc Int Open.* (2015) 03:E91–8. doi: 10.1055/s-0034-1390747